| Racial disparity in efficacy of docosahexaenoic acid supplementation for prevention of preterm birth: secondary analysis from a randomized, double-blind trial 2024 · low-dose DHA · Pregnant individuals enrolled before 20 weeks’ gestation; analyzed by Black and non-Black race/ethnicity | 200 mg | — | 492 |
| Higher-Dose DHA Supplementation Modulates Immune Responses in Pregnancy and Is Associated with Decreased Preterm Birth 2021 · 200 mg group · Pregnant women; age and sex beyond pregnancy not specified | 200 mg | — | 437 |
| A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy 2003 · 133 mg DHA group · Pregnant women enrolled between the 24th and 28th week of pregnancy | 133 mg | — | — |
| Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation 2023 · 200 mg/day DHA group · Pregnant adults aged 18 years or older with a singleton pregnancy, enrolled before 20 weeks’ gestation | 200 mg | — | — |
| Effects of docosahexaenoic acid supplementation during pregnancy on gestational age and size at birth: randomized, double-blind, placebo-controlled trial in Mexico 2010 · DHA group · Pregnant women aged 18 to 35 years | 400 mg | — | 547 |
| Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy 2023 · 200 mg DHA group · Pregnant adults aged 18 or older, enrolled at 12–20 weeks’ gestation | 200 mg | — | 524 |
| Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa 2003 · docosahexaenoic acid · Male patients with X-linked retinitis pigmentosa; mean age 16 years | 400 mg | 4 years | — |
| The Effect of Omega-3 Docosahexaenoic Acid Supplementation on Gestational Length: Randomized Trial of Supplementation Compared to Nutrition Education for Increasing n-3 Intake from Foods 2015 · 300 mg DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 16–20 weeks’ gestation; low-income antenatal clinic population | 300 mg | — | — |
| Growth patterns in infants born to women with pregestational overweight/obesity supplemented with docosahexaenoic acid during pregnancy 2024 · PGO-200 group · Pregnant women with pregestational overweight or obesity; age and sex beyond pregnancy not specified | 200 mg | — | 81 |
| The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease 2013 · DHA 250 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not stated) | 250 mg | 2 years | 20 |
| [Docosahexaenoic acid benefits on growth and body composition of septic neonates. Randomized trial] 2025 · DHA group · Term and preterm neonates with late-onset sepsis who required surgery | 100 mg | 2 weeks | 18 |
| Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates 2006 · DHA group · Neonates who developed sepsis after a surgical procedure | 100 mg | 2 weeks | 16 |
| DHA Supplementation During Pregnancy Enhances Maternal Vagally Mediated Cardiac Autonomic Control in Humans 2023 · 200 mg/d DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks of gestation | 200 mg | — | — |
| Effects of Prenatal DHA Dose on Infant Visual Attention 2025 · 200 mg/day DHA group · Pregnant women; maternal age and specific eligibility condition not reported | 200 mg | — | — |
| Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants 2017 · DHA group · Preterm infants born before 29 weeks of gestation | 60 mg/kg | — | 592 |
| Racial disparity in efficacy of docosahexaenoic acid supplementation for prevention of preterm birth: secondary analysis from a randomized, double-blind trial 2024 · high-dose DHA · Pregnant individuals enrolled before 20 weeks’ gestation; analyzed by Black and non-Black race/ethnicity | 1 g | — | 540 |
| Efficacy of Docosahexaenoic Acid for the Prevention of Necrotizing Enterocolitis in Preterm Infants: A Randomized Clinical Trial 2021 · DHA-group · Preterm newborn infants weighing 1000–1500 g, at risk of necrotizing enterocolitis | 75 mg/kg | 2 weeks | 100 |
| Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial 2019 · DHA group · Preterm infants with birth weight 1000 g to less than 1500 g | 75 mg/kg | 2 weeks | 55 |
| A randomized trial of docosahexaenoic acid supplementation during the third trimester of pregnancy 2003 · 33 mg DHA group · Pregnant women enrolled between the 24th and 28th week of pregnancy | 33 mg | — | — |
| The Effect of Omega-3 Docosahexaenoic Acid Supplementation on Gestational Length: Randomized Trial of Supplementation Compared to Nutrition Education for Increasing n-3 Intake from Foods 2015 · 600 mg DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 16–20 weeks’ gestation; low-income antenatal clinic population | 600 mg | — | — |
| Docosahexaenoic acid supplementation (DHA) and the return on investment for pregnancy outcomes 2016 · DHA group · Pregnant women; age not stated; no specific condition stated | 600 mg | — | — |
| Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) 2018 · SC411 20 mg DHA/kg per day · Children aged 5–17 years with sickle cell disease | 20 mg/kg | 4 weeks | — |
| Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) 2018 · SC411 36 mg DHA/kg per day · Children aged 5–17 years with sickle cell disease | 36 mg/kg | 4 weeks | — |
| Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial) 2018 · SC411 60 mg DHA/kg per day · Children aged 5–17 years with sickle cell disease | 60 mg/kg | 4 weeks | — |
| Dose-response relationship between docosahexaenoic acid (DHA) intake and lower rates of early preterm birth, low birth weight and very low birth weight 2018 · 600 mg DHA/d group · Pregnant women with healthy singleton pregnancies, recruited before 20 weeks’ gestation | 600 mg | — | — |
| Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder 2019 · DHA group · Adults with major depressive disorder | 1.4 g | 12 weeks | — |
| Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation 2023 · 800 mg/day DHA group (PANDA trial) · Pregnant adults aged 18 years or older with a singleton pregnancy, enrolled before 20 weeks’ gestation | 800 mg | — | — |
| Docosahexaenoic acid (DHA) intake estimated from a 7-question survey identifies pregnancies most likely to benefit from high-dose DHA supplementation 2023 · 1000 mg/day DHA group (ADORE trial) · Pregnant adults aged 18 years or older with a singleton pregnancy, enrolled before 20 weeks’ gestation | 1 g | — | — |
| Prenatal Docosahexaenoic Acid Supplementation and Offspring Development at 18 Months: Randomized Controlled Trial 2015 · DHA · Pregnant women aged 18–35 years, enrolled at 18–22 weeks of gestation | 400 mg | — | 365 |
| Maternal FADS2 single nucleotide polymorphism modified the impact of prenatal docosahexaenoic acid (DHA) supplementation on child neurodevelopment at 5 years: Follow-up of a randomized clinical trial 2021 · DHA intervention group · Pregnant women enrolled at 18–22 weeks of gestation; maternal age range and health conditions not specified | 400 mg | — | 316 |
| Short-Term Omega 3 Fatty Acids Treatment for Dry Eye in Young and Middle-Aged Visual Display Terminal Users 2016 · O3FA group · Young and middle-aged visual display terminal users with dry eye symptoms | 240 mg | 45 days | 256 |
| Essential n-3 fatty acids in pregnant women and early visual acuity maturation in term infants 2008 · DHA · Pregnant women, from 16 weeks’ gestation until delivery | 400 mg | — | 67 |
| Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity 2009 · fish-oil intervention group · Adults with metabolic syndrome; mean age 52.9 years; sex not specified | 120 mg | 26 weeks | 60 |
| Pilot study on the effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on body composition in children with acute lymphoblastic leukemia: randomized clinical trial 2023 · LCPUFA-ω3 group · Children aged 3–13 years with newly diagnosed acute lymphoblastic leukemia | 225 mg | 90 days | 36 |
| Short-term consumption of oral omega-3 and dry eye syndrome 2013 · treatment group · Patients aged 45–90 years with dry eye symptoms | 240 mg | 30 days | 33 |
| Maturation of visual acuity is accelerated in breast-fed term infants fed baby food containing DHA-enriched egg yolk 2004 · DHA-enriched egg-yolk baby food group · Breast-fed infants assigned at 6 months of age | 83 mg | 26 weeks | 25 |
| A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa 2004 · +DHA group · Male patients with X-linked retinitis pigmentosa, ages 4–38 years (mean age 16 years) | 400 mg | 4 years | 23 |
| The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease 2013 · DHA 500 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not stated) | 500 mg | 2 years | 20 |
| Eicosapentaenoic Acid-Rich Fish Oil Supplementation Inhibits the Decrease in Concentric Work Output and Muscle Swelling of the Elbow Flexors 2019 · EPA group · Healthy men; age not stated | 260 mg | 8 weeks | 8 |
| Does maternal docosahexaenoic acid supplementation during pregnancy and lactation lower BMI in late infancy? 2007 · BSF plus fish oil DHA · Pregnant women enrolled at 21 weeks' gestation; followed through lactation | 200 mg | — | — |
| Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study 2010 · low-dose DHA · Healthy boys aged 8–10 years | 400 mg | 8 weeks | — |
| The efficacy of omega-3 supplementation for major depression: a randomized controlled trial 2011 · omega-3 supplementation · Adult outpatients experiencing a major depressive episode lasting at least 4 weeks | 150 mg | 8 weeks | — |
| Prenatal docosahexaenoic acid supplementation and infant morbidity: randomized controlled trial 2011 · DHA group · Pregnant women in Mexico; maternal age and health condition not reported | 400 mg | — | — |
| Omega-3 fatty acid supplementation during pregnancy and respiratory symptoms in children 2014 · DHA · Pregnant women aged 18–35 years; infant respiratory symptoms were assessed, with reported effects among infants of atopic mothers | 400 mg | — | — |
| Maternal single nucleotide polymorphisms in the fatty acid desaturase 1 and 2 coding regions modify the impact of prenatal supplementation with DHA on birth weight 2016 · DHA intervention group · Pregnant Mexican women, from weeks 18–22 of gestation through delivery | 400 mg | — | — |
| Prenatal supplementation with DHA improves attention at 5 y of age: a randomized controlled trial 2016 · DHA group · Pregnant Mexican women; offspring assessed at age 5 years | 400 mg | — | — |
| Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function 2018 · 0.5 g DHA group · Infertile men; age and sex details beyond male participants are not reported | 500 mg | 90 days | — |
| Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial 2020 · DP group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function | 465 mg | 12 weeks | — |
| Docosahexaenoic Acid Supplementation During Pregnancy and Lactation and Infant Morbidity: Findings from DHANI Trial 2025 · DHA group · Healthy pregnant women aged 18–35 years, from 20 weeks’ gestation or earlier through 6 months postpartum | 400 mg | — | — |
| Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis 2026 · fish-oil group · Adults receiving maintenance hemodialysis | 800 mg | 1278 days | 610 |
| Early and late preterm birth rates in participants adherent to randomly assigned high dose docosahexaenoic acid (DHA) supplementation in pregnancy 2023 · 1000 mg DHA group · Pregnant adults aged 18 or older, enrolled at 12–20 weeks’ gestation | 800 mg | — | 576 |
| Higher-Dose DHA Supplementation Modulates Immune Responses in Pregnancy and Is Associated with Decreased Preterm Birth 2021 · 1000 mg group · Pregnant women; age and sex beyond pregnancy not specified | 800 mg | — | 465 |
| Fish consumption, erythrocyte fatty acids, and preterm birth 2011 · omega-3 supplementation · Pregnant women with a history of at least one previous spontaneous singleton preterm birth | 800 mg | 146 days | 434 |
| Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial 2012 · n-3 LCPUFA group · Pregnant women from Adelaide whose unborn baby had a mother, father, or sibling with a history of medically diagnosed allergic disease | 800 mg | — | 368 |
| n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes 2011 · EPA-DHA · Adults aged 60–80 with diabetes and a previous myocardial infarction | 149 mg | 1217 days | 262 |
| CFH Y402H and ARMS2 A69S Polymorphisms and Oral Supplementation with Docosahexaenoic Acid in Neovascular Age-Related Macular Degeneration Patients: The NAT2 Study 2015 · DHA group · Adults aged 55–85 with early AMD in the study eye and neovascular AMD in the fellow eye | 840 mg | 3 years | 127 |
| Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT) 2002 · omega-3 FA group · Patients undergoing balloon-only percutaneous transluminal coronary angioplasty (PTCA) | 2.1 g | 240 days | 125 |
| Effect of Enteral Lipid Supplement on Severe Retinopathy of Prematurity: A Randomized Clinical Trial 2021 · AA:DHA group · Extremely preterm infants born before 28 weeks’ gestational age | 50 mg/kg | 92 days | 101 |
| Platelet characteristics in extremely preterm infants after fatty acid supplementation: a randomized controlled trial 2025 · AA/DHA supplement · Extremely preterm infants born before 28 weeks’ gestational age | 50 mg/kg | — | 84 |
| Allergic disease in infants up to 2 years of age in relation to plasma omega-3 fatty acids and maternal fish oil supplementation in pregnancy and lactation 2011 · ω-3-supplemented group · Pregnant women at risk of having an allergic infant, starting in the 25th gestational week and continuing through breastfeeding | 1.1 g | — | 54 |
| Fish oil supplementation in pregnancy and lactation may decrease the risk of infant allergy 2009 · omega-3 group · Pregnant and breastfeeding women with an allergy themselves or a husband or previous child with allergies | 1.1 g | — | 52 |
| Change in Blood and Benign Breast Biomarkers in Women Undergoing a Weight-Loss Intervention Randomized to High-Dose ω-3 Fatty Acids versus Placebo 2021 · ω-3-FA · Peri- and postmenopausal women younger than 70 with BMI ≥28 and increased breast-cancer risk | 1.05 g | 1 year | 23 |
| The N-3 polyunsaturated fatty acids supplementation to prevent depression recurrence in patients with late-life depression: A 52-week double-blind, placebo-controlled trial 2025 · n-3 PUFAs group · Patients with late-life depression who were euthymic at enrollment; ages and sex not reported | 1 g | 52 weeks | 19 |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 350 mg | 5 years | — |
| Randomized clinical trial of perioperative omega-3 fatty acid supplements in elective colorectal cancer surgery 2014 · n-3 FA-enriched oral nutritional supplement group · Adults with colorectal cancer referred for elective colorectal cancer surgery; ages 41–89 years, women and men | 1 g | 2 weeks | — |
| Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder 2019 · EPA + DHA group · Adults with major depressive disorder | 700 mg | 12 weeks | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + placebo · Women in early pregnancy | 1.9 g | — | — |
| Enteral supplementation with arachidonic and docosahexaenoic acid and pulmonary outcome in extremely preterm infants 2024 · AA and DHA supplementation · Extremely preterm infants | 50 mg/kg | — | — |
| Docosahexaenoic acid supplementation and time at achievement of gross motor milestones in healthy infants: a randomized, prospective, double-blind, placebo-controlled trial 2009 · DHA · Healthy neonates followed throughout the first year of life | 20 mg | 1 year | 580 |
| Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial 2015 · standard-DHA diet · Infants born before 33 weeks’ gestation | 20 mg/kg | — | 313 |
| Neurodevelopmental outcomes at 7 years' corrected age in preterm infants who were fed high-dose docosahexaenoic acid to term equivalent: a follow-up of a randomised controlled trial 2015 · high-DHA diet · Infants born before 33 weeks’ gestation | 50 mg/kg | — | 291 |
| Effect of Maternal Docosahexaenoic Acid Supplementation on Very Preterm Infant Growth: Secondary Outcome of a Randomized Clinical Trial 2022 · DHA group · Lactating mothers who delivered before 29 weeks’ gestation; their breastfed very preterm infants were assessed for growth. | 1.2 g | — | 273 |
| Docosahexaenoic acid for reading, cognition and behavior in children aged 7-9 years: a randomized, controlled trial (the DOLAB Study) 2012 · Active · Healthy children, mainly aged 7–9 years, attending mainstream schools and selected for below-average reading performance | 600 mg | 16 weeks | 180 |
| Fatty acids and sleep in UK children: subjective and pilot objective sleep results from the DOLAB study--a randomized controlled trial 2014 · Active treatment · Healthy children aged approximately 6–10 years who were underperforming in reading; not selected for sleep problems | 600 mg | 16 weeks | 180 |
| Possible effect of DHA intake on body weight reduction and lipid metabolism in obese children 2011 · DHA and EPA intake · Obese children aged 8–12 years | 300 mg | 3 weeks | 120 |
| DHA supplementation improves cognitive function via enhancing Aβ-mediated autophagy in Chinese elderly with mild cognitive impairment: a randomised placebo-controlled trial 2018 · intervention (DHA) · Elderly Chinese adults with mild cognitive impairment | 2 g | 2 years | 120 |
| Effects of DHA Supplementation on Hippocampal Volume and Cognitive Function in Older Adults with Mild Cognitive Impairment: A 12-Month Randomized, Double-Blind, Placebo-Controlled Trial 2017 · DHA group · Adults aged 65 years and over with mild cognitive impairment | 2 g | 1 year | 110 |
| Growth patterns in infants born to women with pregestational overweight/obesity supplemented with docosahexaenoic acid during pregnancy 2024 · PGO-800 group · Pregnant women with pregestational overweight or obesity; age and sex beyond pregnancy not specified | 800 mg | — | 88 |
| The effect of fish oil on physical aggression in schoolchildren--a randomized, double-blind, placebo-controlled trial 2005 · fish oil group · Japanese schoolchildren aged 9–12 years, girls and boys | 514 mg | 90 days | 83 |
| Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage 2024 · DHA · Adults aged 60 years and older with mild cognitive impairment | 800 mg | 1 year | 70 |
| Supplementation of medium-chain triglycerides combined with docosahexaenoic acid improves cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial 2025 · DHA group · Chinese older adults with mild cognitive impairment | 800 mg | 1 year | 70 |
| Dietary supplementation with docosahexaenoic acid (DHA) improves seminal antioxidant status and decreases sperm DNA fragmentation 2016 · DHA group · Men who were study subjects; age and condition not specified | 1.5 g | 10 weeks | 42 |
| The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial 2013 · EPA-rich fish oil supplementation · Pregnant women aged 18 years or older, at 12–20 weeks’ gestation and at increased risk for depression, without current major depressive disorder | 274 mg | — | 39 |
| Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women 2007 · DHA treatment · Healthy men and women aged 40–65 years | 700 mg | 90 days | 38 |
| Docosahexaenoic acid in the treatment of rheumatoid arthritis: A double-blind, placebo-controlled, randomized cross-over study with microalgae vs. sunflower oil 2018 · microalgae oil (DHA) · Patients with defined rheumatoid arthritis | 2.1 g | 10 weeks | 38 |
| Effects of docosahexaenoic acid supplementation during pregnancy on fetal heart rate and variability: a randomized clinical trial 2013 · DHA group · Pregnant women aged 16–35.9 years with singleton pregnancies, enrolled between 12 and 20 weeks of gestation; serious maternal or fetal health conditions were excluded. | 600 mg | — | 35 |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 400 mg | 16 weeks | 31 |
| Does antenatal supplementation with omega-3 affect child development and behavior during the first six months of life? A randomized double-blind placebo-controlled trial 2023 · omega-3 · Low-risk pregnant women recruited at 22–24 weeks of gestation | 1.44 g | — | 30 |
| Docosahexaenoic Acid Slows Visual Field Progression in X-Linked Retinitis Pigmentosa: Ancillary Outcomes of the DHAX Trial 2015 · DHA group · Male participants aged 7–31 years with X-linked retinitis pigmentosa | 30 mg/kg | 4 years | 29 |
| Effect of a Novel Omega-3 and Omega-6 Fatty Acid Supplement on Dry Eye Disease: A 3-month Randomized Controlled Trial 2022 · treatment supplement · Participants with moderate to severe dry eye disease | 300 mg | 90 days | 24 |
| A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder 2019 · OM · Children aged 2.5–8 years with autism spectrum disorder | 722 mg | 1 year | 23 |
| Docosahexaenoic acid (DHA) supplementation in atopic eczema: a randomized, double-blind, controlled trial 2008 · DHA · Adults aged 18–40 with atopic eczema | 5.4 g | 8 weeks | 21 |
| Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study 2004 · DHA supplementation · Children aged 9–19 years with familial hypercholesterolemia or the phenotype of familial combined hyperlipidemia | 1.2 g | 6 weeks | 20 |
| Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women 2008 · DHA · Women aged 60–80 years without stated cognitive impairment | 800 mg | 120 days | 14 |
| A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder 2008 · Group A · Adult outpatients with major depressive disorder; mean age 42 years, 46% women | 1 g | 12 weeks | 14 |
| The Effect of DHA Supplementation on Cognition in Patients with Bipolar Disorder: An Exploratory Randomized Control Trial 2020 · BD patients with Omega 3 · Adults aged 18–65 with euthymic bipolar disorder type I or II | 1.25 g | 12 weeks | 13 |
| A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder 2008 · Group B · Adult outpatients with major depressive disorder; mean age 42 years, 46% women | 2 g | 12 weeks | 11 |
| Omega-3 polyunsaturated fatty acids protect against inflammation through production of LOX and CYP450 lipid mediators: relevance for major depression and for human hippocampal neurogenesis 2021 · DHA · Adults with major depressive disorder meeting DSM-IV criteria and baseline 21-item Hamilton Rating Scale for Depression scores of at least 18; sex and age range not reported | 1.4 g | 12 weeks | 11 |
| Impact of 1-Year Supplementation with High-Rich Docosahexaenoic Acid (DHA) on Clinical Variables and Inflammatory Biomarkers in Pediatric Cystic Fibrosis: A Randomized Double-Blind Controlled Trial 2024 · DHA group · Children aged 6–18 years with cystic fibrosis | 50 mg/kg | 1 year | 11 |
| A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorder 2008 · Group C · Adult outpatients with major depressive disorder; mean age 42 years, 46% women | 4 g | 12 weeks | 10 |
| Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38 2017 · DHA treatment, open-label phase · Adults with spinocerebellar ataxia type 38 due to the p.Gly230Val mutation; ages 35–73 years; both sexes | 600 mg | 40 weeks | 10 |
| The Effect of DHA Supplementation on Cognition in Patients with Bipolar Disorder: An Exploratory Randomized Control Trial 2020 · HCs with Omega 3 · Healthy adults aged 18–65 without DSM-IV Axis I disorders | 1.25 g | 12 weeks | 7 |
| Long-Chain Omega-3 Fatty Acid Supplementation and Exercise-Induced Muscle Damage: EPA or DHA? 2024 · DHA · Males; age and health status not reported | 4 g | 52 days | 7 |
| Docosahexaenoic acid is a beneficial replacement treatment for spinocerebellar ataxia 38 2017 · DHA group, randomized double-blind phase · Adults with spinocerebellar ataxia type 38 due to the p.Gly230Val mutation; ages 35–73 years; both sexes | 600 mg | 16 weeks | 5 |
| Differential effects of eicosapentaenoic acid and docosahexaenoic acid on vascular reactivity of the forearm microcirculation in hyperlipidemic, overweight men 2000 · DHA · Overweight, mildly hyperlipidemic men | 4 g | 6 weeks | — |
| Docosahexaenoic acid supplementation increases prefrontal cortex activation during sustained attention in healthy boys: a placebo-controlled, dose-ranging, functional magnetic resonance imaging study 2010 · high-dose DHA · Healthy boys aged 8–10 years | 1.2 g | 8 weeks | — |
| Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline 2010 · DHA · Healthy adults aged 55 and older with age-related cognitive decline | 900 mg | 24 weeks | — |
| Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial 2013 · DHA group · Adults with mild-to-moderate depression receiving maintenance medication | 1 g | 12 weeks | — |
| DHA supplementation improved both memory and reaction time in healthy young adults: a randomized controlled trial 2013 · DHA group · Healthy adults aged 18–45 years, nonsmoking and with low DHA intake | 1.16 g | 26 weeks | — |
| Docosahexaenoic Acid and Periodontitis in Adults: A Randomized Controlled Trial 2014 · DHA group · Adults with moderate periodontitis | 2 g | 90 days | — |
| Beneficial effects of dietary docosahexaenoic acid intervention on cognitive function and mental health of the oldest elderly in Japanese care facilities and nursing homes 2017 · active group · Elderly care-facility and nursing-home residents, mean age 88.5 years, with cognitive impairment such as dementia | 1.72 g | 1 year | — |
| Prenatal DHA supplementation and infant attention 2016 · Supplemented group · Pregnant women; maternal age and health condition are not specified | 600 mg | — | — |
| Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function 2018 · 1 g DHA group · Infertile men; age and sex details beyond male participants are not reported | 1 g | 90 days | — |
| Effect of dietary supplementation with a highly pure and concentrated docosahexaenoic acid (DHA) supplement on human sperm function 2018 · 2 g DHA group · Infertile men; age and sex details beyond male participants are not reported | 2 g | 90 days | — |
| [Docosahexaenoic acid in the treatment of idiopathic male infertility] 2019 · active treatment group · Infertile men with idiopathic male infertility | 1.05 g | 90 days | — |
| Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial 2021 · DHA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified | 800 mg | 26 weeks | — |
| Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial 2021 · DHA · Adults aged over 60 years with mild cognitive impairment | 800 mg | 26 weeks | — |
| DHA Supplementation During Pregnancy Enhances Maternal Vagally Mediated Cardiac Autonomic Control in Humans 2023 · 800 mg/d DHA · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks of gestation | 800 mg | — | — |
| Effects of Prenatal DHA Dose on Infant Visual Attention 2025 · 800 mg/day DHA group · Pregnant women; maternal age and specific eligibility condition not reported | 800 mg | — | — |
| Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans 1998 · DHA group · Healthy, nonsmoking men aged 36–56 years | 4 g | — | — |
| Cow's milk-based beverage consumption in 1- to 4-year-olds and allergic manifestations: an RCT 2016 · CMBB · Children aged 1 to 4 years attending daycare in Brazil; generally healthy, without a stated diagnosed condition | 75 mg | 28 weeks | 125 |
| The effect of prenatal docosahexaenoic acid supplementation on infant outcomes in African American women living in low-income environments: A randomized, controlled trial 2016 · Active supplement (groups B and C; identical doses) · African American pregnant women aged 20–30 living in low-income environments, with sea fish consumption below 2 servings per week | 450 mg | — | 43 |
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 350 mg | 5 years | — |
| Maternal fish oil and/or probiotics intervention: Allergic diseases in children up to two years old 2023 · fish oil + probiotics · Women in early pregnancy | 1.9 g | — | — |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO + CUR group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 400 mg | 16 weeks | 30 |
| The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT) 2021 · Omega 3 Polyunsaturated Fatty Acids · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait | 400 mg | 3 years | 381 |
| The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT) 2021 · Combined intervention · Community-dwelling adults aged 70 years and older with a spontaneous memory complaint, limitation in one instrumental activity of daily living, or slow gait | 400 mg | 3 years | 374 |
| Prenatal Fish Oil Supplementation and Allergy: 6-Year Follow-up of a Randomized Controlled Trial 2016 · n-3 LCPUFA-rich fish oil capsules · Pregnant women with a family history of allergic disease | 800 mg | — | 367 |
| The Influence of Prenatal DHA Supplementation on Individual Domains of Behavioral Functioning in School-Aged Children: Follow-Up of a Randomized Controlled Trial 2021 · DHA-rich fish oil · Pregnant women with singleton pregnancies enrolled before 21 weeks’ gestation; no specific diagnosed condition stated | 800 mg | — | 351 |
| Effect of Omega-3 on HLA-DR Expression by Conjunctival Cells and Tear Cytokine Concentrations in the Dry Eye Assessment and Management Study 2022 · active supplement group (ω3) · Adults with moderate to severe dry eye disease | 1 g | 1 year | 349 |
| Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye 2015 · O3FA group · Symptomatic computer users using computers more than 3 hours per day for at least 1 year; sex and age not specified; computer vision syndrome-related dry eye | 240 mg | 90 days | 220 |
| Docosahexaenoic Acid and Arachidonic Acid Supplementation and Sleep in Toddlers Born Preterm: Secondary Analysis of a Randomized Clinical Trial 2019 · DHA+AA supplementation · Children aged 10 to 16 months at enrollment, born before 35 weeks' gestation | 200 mg | 180 days | 193 |
| Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a randomized controlled trial in young adults 2013 · DHA supplemented group · Healthy adults aged 18–37 years, men and women, without chronic disease likely to affect endothelial function | 1.6 g | 120 days | 162 |
| Fatty Acid Supplementation and Socioemotional Outcomes: Secondary Analysis of a Randomized Trial 2020 · DHA + AA · Children aged 10 to 16 months at enrollment, born at less than 35 weeks' gestation | 200 mg | 180 days | 161 |
| Effects of Varied Omega-3 Fatty Acid Supplementation on Postpartum Mental Health and the Association between Prenatal Erythrocyte Omega-3 Fatty Acid Levels and Postpartum Mental Health 2023 · fish oil group · Healthy primiparous pregnant women aged 19–45 years | 400 mg | 12 weeks | 124 |
| The effects of docosahexaenoic acid-rich fish oil on behavior, school attendance rate and malaria infection in school children--a double-blind, randomized, placebo-controlled trial in Lampung, Indonesia 2008 · DHA group · Fourth- to sixth-grade school children, mostly aged 9–12 years, in Lampung, Indonesia | 650 mg | 90 days | 116 |
| Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials 2021 · DHA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use | 900 mg | 26 weeks | 113 |
| Supplementation with oil rich in eicosapentaenoic acid, but not in docosahexaenoic acid, improves global cognitive function in healthy, young adults: results from randomized controlled trials 2021 · EPA-rich oil · Healthy adults aged 25–49 who habitually consumed oily fish less than once per week and reported no habitual dietary supplement use | 360 mg | 26 weeks | 112 |
| Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized, double-blind, placebo-controlled intervention trial 2009 · fish oil · Thai schoolchildren aged 9 to 12 years | 1 g | 26 weeks | 94 |
| Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study 2009 · Omega-3/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease | 1.7 g | 1 year | 89 |
| Homocysteine Status Modifies the Treatment Effect of Omega-3 Fatty Acids on Cognition in a Randomized Clinical Trial in Mild to Moderate Alzheimer's Disease: The OmegAD Study 2019 · omega-3 fatty acid supplementation · Community-based patients with mild to moderate Alzheimer's disease, MMSE ≥15; 88 participants received supplementation | 1.7 g | 26 weeks | 88 |
| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 200 mg | 26 weeks | 87 |
| Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer's disease: the omega-3 Alzheimer's disease study 2009 · Placebo/Omega-3 group · Adults aged about 73 years with mild to moderate Alzheimer's disease | 1.7 g | 26 weeks | 85 |
| Evaluation of the Retinopathy of Prematurity Activity Scale (ROP-ActS) in a randomised controlled trial aiming for prevention of severe ROP: a substudy of the Mega Donna Mega trial 2022 · AA:DHA · Infants born before 28 weeks of gestational age | 50 mg/kg | — | 84 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Fish oil + placebo · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 3.8 g | — | 82 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Probiotics + fish oil · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 3.8 g | — | 82 |
| The effect of perinatal fish oil supplementation on neurodevelopment and growth of infants: a randomized controlled trial 2018 · fish oil supplementation group · Pregnant women aged 18–35 years | 120 mg | — | 75 |
| Cognitive Benefits of Folic Acid, Docosahexaenoic Acid, and a Combination of Both Nutrients in Mild Cognitive Impairment: Possible Alterations through Mitochondrial Function and DNA Damage 2024 · FA + DHA · Adults aged 60 years and older with mild cognitive impairment | 800 mg | 1 year | 70 |
| Supplementation of medium-chain triglycerides combined with docosahexaenoic acid improves cognitive function in Chinese older adults with mild cognitive impairment: A randomized double-blind, placebo-controlled trial 2025 · MCT + DHA group · Chinese older adults with mild cognitive impairment | 800 mg | 1 year | 70 |
| Developmental Outcomes at 24 Months of Age in Toddlers Supplemented with Arachidonic Acid and Docosahexaenoic Acid: Results of a Double Blind Randomized, Controlled Trial 2017 · DHA/ARA supplement group · Healthy term-born toddlers enrolled at 12–14 months of age | 200 mg | 1 year | 68 |
| Re-Esterified Triglyceride ω-3 Fatty Acids in Dry Eye Disease With Meibomian Gland Dysfunction: A Randomized Clinical Trial 2024 · ω-3 group · Korean adults aged 20–75 with dry eye disease and concurrent meibomian gland dysfunction; both sexes | 560 mg | 12 weeks | 66 |
| Effects of Marine n-3 Polyunsaturated Fatty Acids on Heart Rate Variability and Heart Rate in Patients on Chronic Dialysis: A Randomized Controlled Trial 2018 · n-3 PUFA group · Adults over 18 years receiving chronic dialysis for more than 3 months | 1 g | 90 days | 56 |
| Long-chain Polyunsaturated Fatty Acid Supplementation Improves Mood in Elderly Japanese Men 2017 · LCPUFA group · Japanese men aged 55–64 years | 300 mg | 4 weeks | 51 |
| The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial 2017 · n-3 PUFA · Chinese adults aged 60 years or older with mild cognitive impairment | 480 mg | 26 weeks | 44 |
| Foods, nutrients or whole diets: effects of targeting fish and LCn3PUFA consumption in a 12mo weight loss trial 2013 · Fish + S · Adults aged 18–60 years with overweight or obesity (BMI 25–37 kg/m²), otherwise healthy | 210 mg | 1 year | 40 |
| The Mothers, Omega-3, and Mental Health Study: a double-blind, randomized controlled trial 2013 · DHA-rich fish oil supplementation · Pregnant women aged 18 years or older, at 12–20 weeks’ gestation and at increased risk for depression, without current major depressive disorder | 900 mg | — | 38 |
| Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years 2020 · FO · Healthy pregnant women; offspring were assessed at 7.5 and 9 years | 500 mg | — | 38 |
| Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years 2020 · FO + 5-MTHF · Healthy pregnant women; offspring were assessed at 7.5 and 9 years | 500 mg | — | 36 |
| Cognitive assessment of children at age 2(1/2) years after maternal fish oil supplementation in pregnancy: a randomised controlled trial 2008 · fish oil group · Pregnant women receiving supplementation from 20 weeks’ gestation until delivery; their children were assessed at age 2.5 years | 2.2 g | — | 33 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 71.9 mg/kg | 1 year | 33 |
| Effect of Docosahexaenoic Acid and Eicosapentaenoic Acid Supplementation on Sleep Quality in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial 2022 · DHA/EPA supplementation group · Healthy Japanese adults aged 45 years or older with poor sleep quality; male and female | 576 mg | 12 weeks | 33 |
| The Efficacy of Omega-3 Fatty Acids as the Monotherapy for Depression: A Randomized, Double-Blind, Placebo-Controlled Pilot Study 2024 · n-3 PUFAs group · Adults aged 18–65 with major depressive disorder and HRSD-21 score >18 | 1.1 g | 12 weeks | 30 |
| Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial 2021 · DHA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week | 900 mg | 26 weeks | 29 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 600 mg | 90 days | 27 |
| Differential Effects of DHA- and EPA-Rich Oils on Sleep in Healthy Young Adults: A Randomized Controlled Trial 2021 · EPA-rich oil group · Healthy adults aged 25–49 years, male and female, consuming oily fish less than once per week | 360 mg | 26 weeks | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 780 mg | 12 weeks | 27 |
| Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment 2018 · FO + BB · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment | 800 mg | 24 weeks | 26 |
| Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial 2021 · Risperidone + fish oil (FO) · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum and bipolar disorder with psychosis | 400 mg | 16 weeks | 25 |
| Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial 2007 · n-3 EFA group · Patients presenting after recurrent self-harm | 900 mg | 12 weeks | 22 |
| Cognitive response to fish oil, blueberry, and combined supplementation in older adults with subjective cognitive impairment 2018 · FO · Men and women aged 62–80 with mild self-perceived cognitive decline and no objective cognitive impairment | 800 mg | 24 weeks | 21 |
| Effects of combining exercise with long-chain polyunsaturated fatty acid supplementation on cognitive function in the elderly: a randomised controlled trial 2020 · Ex + LCPUFA · Japanese adults aged 60–79 who were not exercising regularly, had age-related cognitive-decline complaints and lower memory scores, and did not have dementia; exercise arm participants had low skeletal muscle mass in the reported subgroup analysis | 300 mg | 24 weeks | 21 |
| Emotion-Related Network Reorganization Following Fish Oil Supplementation in Depressed Bipolar Offspring: An fMRI Graph-Based Connectome Analysis 2021 · Fish oil · Patients aged 9–21 with a depressive disorder and a biological parent with bipolar I disorder | 780 mg | 12 weeks | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · First group: fish oil followed by placebo · Adolescent girls with dysmenorrhea | 720 mg | 60 days | 21 |
| Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents 1996 · Second group: placebo followed by fish oil · Adolescent girls with dysmenorrhea | 720 mg | 60 days | 21 |
| Effects of dietary omega-3 fatty acid supplementation on endothelium-dependent vasodilation in patients with chronic heart failure 2006 · omega-3 fatty acid · Adults aged 65 years or older with grade II or III chronic heart failure | 1.2 g | 6 weeks | 20 |
| Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder 2012 · citalopram + omega-3 treatment group · Adults aged 18–65 with major depressive disorder and HAM-D score greater than 17 | 200 mg | 8 weeks | 20 |
| Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects 1990 · low-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified | 18 mg/kg | 24 weeks | 20 |
| Omega-3 polyunsaturated fatty acids-enriched hen eggs consumption enhances microvascular reactivity in young healthy individuals 2018 · OMEGA-3 group · Young healthy individuals; age range and sex not specified | 252 mg | 3 weeks | 20 |
| Omega-3 polyunsaturated fatty acids (n-3 PUFAs), somatic and fatigue symptoms in cardiovascular diseases comorbid major depressive disorder (MDD): A randomized controlled trial 2023 · n-3 PUFAs group · Adults with cardiovascular diseases comorbid with major depressive disorder; mean age 60 ± 9 years, 58% male | 1 g | 12 weeks | 20 |
| Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial 2012 · DHA-rich supplement · Adults older than 65 years with mild cognitive impairment | 1.55 g | 26 weeks | 18 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 780 mg | 30 days | 18 |
| Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial 2012 · EPA-rich supplement · Adults older than 65 years with mild cognitive impairment | 160 mg | 26 weeks | 17 |
| Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis. Clinical and immunologic effects 1990 · high-dose fish oil group · Patients with active rheumatoid arthritis; age and sex not specified | 36 mg/kg | 24 weeks | 17 |
| Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial 2013 · fish oil group · People with dry eye syndrome | 540 mg | 12 weeks | 15 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 800 mg | 24 weeks | 15 |
| A randomised controlled trial of vitamin D and omega-3 long chain polyunsaturated fatty acids in the treatment of irritability and hyperactivity among children with autism spectrum disorder 2019 · VIDOM · Children aged 2.5–8 years with autism spectrum disorder | 722 mg | 1 year | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 120 mg | 90 days | 15 |
| Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women 2008 · Combination of DHA and lutein · Women aged 60–80 years without stated cognitive impairment | 800 mg | 120 days | 14 |
| Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers 2008 · PUFA group · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders | 500 mg | 90 days | 13 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 1 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1.22 g | 12 weeks | 13 |
| Omega-3 fatty acid supplementation enhances stroke volume and cardiac output during dynamic exercise 2008 · DHA + EPA · Healthy adult men and women; ages not reported | 2 g | 6 weeks | 12 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 260 mg | 62 days | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 1 g | 12 weeks | 12 |
| 4-week eicosapentaenoic acid-rich fish oil supplementation partially protects muscular damage following eccentric contractions 2021 · EPA and DHA group · Healthy recreationally untrained men; age range not stated | 260 mg | 33 days | 11 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 2 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1.22 g | 12 weeks | 11 |
| Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators 2023 · EPA 4 g/d · Adults with non-psychotic major depressive disorder, BMI >25 kg/m², and low-grade chronic inflammation (hs-CRP ≥3 µg/mL) | 1.22 g | 12 weeks | 11 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 260 mg | 62 days | 10 |
| Omega-3 fatty acids enhance the beneficial effect of BCAA supplementation on muscle function following eccentric contractions 2022 · BCAA+FO group · Healthy, untrained men aged 19–20 years | 260 mg | 61 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 1.58 g | 10 weeks | 10 |
| Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ 2000 · fish oil extract · Patients with distal proctocolitis; age and sex not reported | 2.4 g | 26 weeks | 9 |
| Distal procto-colitis, natural cytotoxicity, and essential fatty acids 1998 · fish oil extract · Patients with distal procto-colitis; age and sex not reported | 2.4 g | 26 weeks | 9 |
| Omega-3 supplementation is neuroprotective to corneal nerves in dry eye disease: a pilot study 2017 · ω-3 EFA supplements · Adults with moderate dry eye disease; age and sex not reported | 500 mg | 90 days | 8 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 260 mg | 62 days | 8 |
| Long-chain n-3 polyunsaturated fatty acids decrease feelings of anger in substance abusers 2008 · PUFA group, six-month follow-up subset · Men admitted to substance abuse clinics, without the listed major physical illnesses or excluded psychiatric disorders | 500 mg | 90 days | 6 |
| Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes 2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported | 2.2 g | 3 weeks | 5 |
| Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis 1992 · Group 2 · Patients with active rheumatoid arthritis | 2 g | 16 weeks | — |
| Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis 1992 · Group 3 · Patients with active rheumatoid arthritis | 2 g | 16 weeks | — |
| Further evaluation of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment: subgroup analyses 2004 · DHA + A group · Adults aged 18 to 55 years with retinitis pigmentosa; subgroup analyses distinguished prior vitamin A use | 1.2 g | 1461 days | — |
| Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions 2006 · omega-3 fatty acids · White men with a history of myocardial infarction and ejection fractions below 40% | 585 mg | 120 days | — |
| Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study 2007 · omega-3 fatty acids · Children aged 5 to 17 years with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior | 700 mg | 6 weeks | — |
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial 2006 · omega-3 fatty acid-treated group · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified | 1.7 g | 26 weeks | — |
| Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial 2006 · placebo group after crossover to omega-3 fatty acid supplementation · Adults with mild to moderate Alzheimer disease, age range 74 ± 9 years; sex not specified | 1.7 g | 26 weeks | — |
| Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety in substance abusers 2008 · PUFA group · Men admitted to substance-abuse outpatient clinics, with polysubstance abuse and suboptimal dietary intake of long-chain n-3 PUFAs | 500 mg | 90 days | — |
| Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults 2008 · Fish oil, no regular physical activity · Sedentary, overweight adults with risk factors for coronary disease | 1.56 g | 12 weeks | — |
| Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults 2008 · Fish oil with regular physical activity · Sedentary, overweight adults with risk factors for coronary disease | 1.56 g | 12 weeks | — |
| Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment 2010 · Intervention group · Patients with stage III non-small cell lung cancer undergoing multimodality treatment; age and sex not specified | 900 mg | 5 weeks | — |
| Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age 2011 · fish-oil group · healthy pregnant women | 500 mg | — | — |
| Effects of prenatal fish-oil and 5-methyltetrahydrofolate supplementation on cognitive development of children at 6.5 y of age 2011 · combined fish-oil and 5-MTHF group · healthy pregnant women | 500 mg | — | — |
| The effect of a 1-year multiple micronutrient or n-3 fatty acid fortified food intervention on morbidity in Indian school children 2012 · High micronutrients + high n-3 fatty acids · Children aged 6–10 years in India | 100 mg | 1 year | — |
| The effect of a 1-year multiple micronutrient or n-3 fatty acid fortified food intervention on morbidity in Indian school children 2012 · Low micronutrients + high n-3 fatty acids · Children aged 6–10 years in India | 100 mg | 1 year | — |
| Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study 2012 · n-3 group · Patients with advanced inoperable non-small-cell lung cancer undergoing chemotherapy | 340 mg | 66 days | — |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 400 mg | 8 weeks | — |
| Effects of high-dose fish oil supplementation during early infancy on neurodevelopment and language: a randomised controlled trial 2012 · DHA-enriched fish oil group · Healthy term infants, from birth to 6 months | 250 mg | 26 weeks | — |
| Fish oil supplementation reduces cortisol basal levels and perceived stress: a randomized, placebo-controlled trial in abstinent alcoholics 2013 · fish-oil supplementation · Adult men with alcohol dependence undergoing residential rehabilitation | 252 mg | 3 weeks | — |
| Improvement of major depression is associated with increased erythrocyte DHA 2013 · HiDHA · Adults receiving treatment for major depression | 2 g | 16 weeks | — |
| Effects of fish oil supplementation on learning and behaviour of children from Australian Indigenous remote community schools: a randomised controlled trial 2013 · fish oil capsules · children aged 3–13 years attending Australian Indigenous remote community schools | 750 mg | 40 weeks | — |
| The effect of omega-3 fatty acids on depressive symptoms and inflammatory markers in maintenance hemodialysis patients: a randomized, placebo-controlled clinical trial 2014 · omega-3 group · Maintenance hemodialysis patients; age range and sex not reported | 360 mg | 120 days | — |
| Effects of omega-3 fatty acids on tobacco craving in cigarette smokers: A double-blind, randomized, placebo-controlled pilot study 2014 · omega-3 fatty acid supplementation · Regular cigarette smokers | 2.04 g | 30 days | — |
| Effects of omega-3 fatty acids on depression and quality of life in maintenance hemodialysis patients 2014 · omega-3 fatty acids group · Adults with depressive symptoms (BDI score ≥16) receiving maintenance hemodialysis for at least 3 months | 720 mg | 120 days | — |
| Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder 2015 · ADHD Active · Boys aged 8–14 with ADHD | 650 mg | 16 weeks | — |
| Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder 2015 · RG Active · Typically developing boys matched to the ADHD participants for age, hand preference, and BMI | 650 mg | 16 weeks | — |
| Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study 2016 · EPA-enriched mix · Adults aged 18–80 with major depressive disorder | 260 mg | 8 weeks | — |
| Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study 2016 · DHA-enriched mix · Adults aged 18–80 with major depressive disorder | 900 mg | 8 weeks | — |
| Low Doses of Long-chain Polyunsaturated Fatty Acids Affect Cognitive Function in Elderly Japanese Men: A Randomized Controlled Trial 2015 · LCPUFA group · Japanese men aged 55–64 years without dementia | 300 mg | 4 weeks | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 350 mg | 5 years | — |
| Effects of omega-3 polyunsaturated fatty acids on psychophysiological symptoms of post-traumatic stress disorder in accident survivors: A randomized, double-blind, placebo-controlled trial 2017 · omega-3 PUFAs · Japanese accident survivors who began supplementation within 10 days of accidental injury | 1.47 g | 12 weeks | — |
| Change in blood levels of eicosapentaenoic acid and posttraumatic stress symptom: A secondary analysis of data from a placebo-controlled trial of omega3 supplements 2016 · omega3 supplements arm · Participants with severe physical injury; age and sex not reported | 1.47 g | 12 weeks | — |
| Omega-3 supplements reduce self-reported physical aggression in healthy adults 2018 · Omega-3 supplements · Adults aged 18–45 from the general population | 638 mg | 6 weeks | — |
| ω-3 and ω-6 Fatty Acid Supplementation May Reduce Autism Symptoms Based on Parent Report in Preterm Toddlers 2018 · Omega-3-6-9 Junior treatment · Children aged 18–38 months born at 29 weeks’ gestation or earlier, exhibiting early signs of ASD | 225 mg | 90 days | — |
| Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial 2018 · omega-3 group · Women with depression and overweight or obesity (BMI ≥25) seeking weight reduction | 720 mg | 12 weeks | — |
| Adding omega-3 fatty acids to a protein-based supplement during pre-season training results in reduced muscle soreness and the better maintenance of explosive power in professional Rugby Union players 2018 · FO · Professional Rugby Union players undergoing pre-season training; age and sex not stated | 1.1 g | 5 weeks | — |
| Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial 2020 · fish oil · Sedentary overweight/obese adults aged 50–80 years | 2 g | 16 weeks | — |
| Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial 2020 · combination of fish oil and curcumin · Sedentary overweight/obese adults aged 50–80 years | 2 g | 16 weeks | — |
| Effects of coadministration of DHA and vitamin E on spermatogram, seminal oxidative stress, and sperm phospholipids in asthenozoospermic men: a randomized controlled trial 2020 · DE group · Men aged 20–45 with idiopathic asthenozoospermia and normal endocrine function | 465 mg | 12 weeks | — |
| Effect of folic acid combined with docosahexaenoic acid intervention on mild cognitive impairment in elderly: a randomized double-blind, placebo-controlled trial 2021 · FA + DHA · Elderly people with mild cognitive impairment (MCI); age range and sex not specified | 800 mg | 26 weeks | — |
| Re-esterified DHA improves ventilatory threshold 2 in competitive amateur cyclists 2020 · DHA · Male amateur cyclists older than 18 years, competing at regional level and training 2–4 sessions per week | 975 mg | 30 days | — |
| Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial 2021 · folic acid + DHA · Adults aged over 60 years with mild cognitive impairment | 800 mg | 26 weeks | — |
| Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women 2021 · omega-3 group (n-3) · Women aged 55–70 who were overweight or obese and postmenopausal | 1.65 g | 16 weeks | — |
| Effects of DHA-Rich n-3 Fatty Acid Supplementation and/or Resistance Training on Body Composition and Cardiometabolic Biomarkers in Overweight and Obese Post-Menopausal Women 2021 · omega-3 + resistance training group (n-3+RT) · Women aged 55–70 who were overweight or obese and postmenopausal | 1.65 g | 16 weeks | — |
| Effect of arachidonic and docosahexaenoic acid supplementation on respiratory outcomes and neonatal morbidities in preterm infants 2023 · intervention · Very preterm infants with gestational age less than 29 weeks | 50 mg/kg | — | — |
| Effect of Docosahexaenoic Acid (DHA) Supplementation of Preterm Infants on Growth, Body Composition, and Blood Pressure at 7-Years Corrected Age: Follow-Up of a Randomized Controlled Trial 2023 · high-DHA diet (intervention) · Preterm infants born before 33 weeks gestation and their breastfeeding mothers; enrolled within 5 days of commencing enteral feeds | 900 mg | — | — |
| Effect of arachidonic and docosahexaenoic acid supplementation on quality of growth in preterm infants: A secondary analysis of a randomized controlled trial 2023 · ARA:DHA group · Infants born before 29 weeks of gestation | 50 mg/kg | — | — |
| Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial 2024 · n-3 PUFAs supplementation · Outpatients with first-diagnosed, drug-naïve depression receiving venlafaxine; age and sex not reported | 960 mg | 12 weeks | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.14 g | 1 year | — |
| High-Dose DHA Has More Profound Effects on LDL-Related Features Than High-Dose EPA: The ComparED Study 2018 · phase 2: DHA · Adults with abdominal obesity and subclinical inflammation at risk of cardiovascular disease; 48 men and 106 women enrolled | 2.7 g | 10 weeks | 154 |
| Effect of Prenatal Docosahexaenoic Acid Supplementation on Blood Pressure in Children With Overweight Condition or Obesity: A Secondary Analysis of a Randomized Clinical Trial 2019 · DHA group · Pregnant women enrolled before 20 weeks’ gestation; no stated health condition | 600 mg | — | 89 |
| LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women 2004 · DHA treatment · Men and women aged 40–65 years | 700 mg | 90 days | 38 |
| Docosahexaenoic acid reduces resting blood pressure but increases muscle sympathetic outflow compared with eicosapentaenoic acid in healthy men and women 2019 · DHA · Healthy young men and women | 3 g | 12 weeks | 28 |
| Ethyl EPA and ethyl DHA cause similar and differential changes in plasma lipid concentrations and lipid metabolism in subjects with low-grade chronic inflammation 2022 · DHA supplementation · Adults aged 50–75 with low-grade chronic inflammation and at least one characteristic of metabolic syndrome; women were postmenopausal | 3 g | 10 weeks | 21 |
| Sodium transport kinetics, cell membrane lipid composition, neural conduction and metabolic control in type 1 diabetic patients. Changes after a low-dose n-3 fatty acid dietary intervention 1999 · supplemented group · Type 1 diabetic patients | 330 mg | — | — |
| Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans 1999 · purified DHA · overweight, mildly hyperlipidemic men | 4 g | 6 weeks | — |
| Impact of DHA from Algal Oil on the Breast Milk DHA Levels of Lactating Women: A Randomized Controlled Trial in China 2022 · supplement group · Healthy lactating women aged 20–40 years, exclusively breastfeeding, 30–50 days postpartum, with no stated disease | 200 mg | 8 weeks | 77 |
| Changes in fatty acid levels after consumption of a novel docosahexaenoic supplement from algae: a crossover randomized controlled trial in omnivorous, lacto-ovo vegetarians and vegans 2023 · DHA-supplement · Healthy adults aged 18–45 consuming a vegetarian diet for at least 6 months or an omnivorous diet with low fish intake | 250 mg | 5 weeks | 51 |
| Supplementation with docosahexaenoic acid in the last trimester of pregnancy: maternal-fetal biochemical findings 2004 · study group (group A) · pregnant women in the last trimester | 200 mg | — | 20 |
| Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food 2007 · DHASCO-T capsules, 200 mg DHA/day · Adults; age, sex, and health condition not specified | 200 mg | 4 weeks | 12 |
| Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food 2007 · DHASCO-S capsules, 200 mg DHA/day · Adults; age, sex, and health condition not specified | 200 mg | 4 weeks | 12 |
| Docosahexaenoic acid transfer into human milk after dietary supplementation: a randomized clinical trial 2000 · DHA-rich oil group · Lactating women, 4–6 weeks postpartum | 200 mg | 2 weeks | 5 |
| Human milk arachidonic acid and docosahexaenoic acid contents increase following supplementation during pregnancy and lactation 2009 · DHA · Women supplemented during pregnancy and lactation | 220 mg | — | — |
| Docosahexaenoic acid (DHA) supplementation of orange juice increases plasma phospholipid DHA content of children 2009 · higher dose · Healthy children aged 4–6 and 7–12 years | 100 mg | 6 weeks | — |
| Toddler formula supplemented with docosahexaenoic acid (DHA) improves DHA status and respiratory health in a randomized, double-blind, controlled trial of US children less than 3 years of age 2010 · 130 mg DHA per day · Children aged 18–36 months, with no condition stated | 130 mg | 60 days | — |
| Docosahexaenoic acid supplementation in pregnancy and early lactation: Impacts on breast milk docosahexaenoic acid and Maternal-Infant gut microbiota - A randomized controlled trial 2025 · FC · Chinese pregnant women receiving supplementation during the third trimester | 100 mg | — | — |
| Docosahexaenoic acid supplementation in pregnancy and early lactation: Impacts on breast milk docosahexaenoic acid and Maternal-Infant gut microbiota - A randomized controlled trial 2025 · FF · Chinese pregnant women who continued supplementation through 42 days postpartum | 100 mg | — | — |
| Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition 1996 · 0.2 g DHA/day group · Lactating mothers, randomised on day 5 postpartum | 200 mg | — | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 400 mg | 18 weeks | 134 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 300 mg | 12 weeks | 96 |
| Omega-3 Fatty Acids, Depressive Symptoms, and Cognitive Performance in Patients With Coronary Artery Disease: Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial 2016 · n-3 PUFA treatment · Men and women aged 45–80 with stable coronary artery disease participating in cardiac rehabilitation, with or without a depressive episode | 600 mg | 12 weeks | 46 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 480 mg | 12 weeks | 40 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 300 mg | 24 weeks | 40 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 430 mg | 2 years | 30 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 400 mg | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 26 weeks | 24 |
| The Effects of a 6-Month High Dose Omega-3 and Omega-6 Polyunsaturated Fatty Acids and Antioxidant Vitamins Supplementation on Cognitive Function and Functional Capacity in Older Adults with Mild Cognitive Impairment 2020 · omega supplementation group · Adults aged 65 years or older with mild cognitive impairment | 4.14 g | 26 weeks | 23 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · EPA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 137 mg | 30 days | 22 |
| Omega-3 fatty acids modify human cortical visual processing--a double-blind, crossover study 2011 · DHA-rich formulation · Healthy adults aged 19–34 years without known neurological or psychiatric conditions | 417 mg | 30 days | 22 |
| Benefits of Krill Oil Supplementation During Alternate-Day Fasting in Adults With Overweight and Obesity: A Randomized Trial 2025 · KO group · Healthy adults aged 25–65 with BMI >25 kg/m² and overweight or obesity; 25 women and 16 men enrolled | 188 mg | 12 weeks | 21 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 1.8 g | 90 days | 20 |
| Neuroaspis PLP10™, a nutritional formula rich in omega-3 and omega-6 fatty acids with antioxidant vitamins including gamma-tocopherol in early Parkinson's disease: A randomized, double-blind, placebo-controlled trial 2021 · Neuroaspis PLP10™ · Patients with Parkinson's disease; age and sex not reported. | 4.14 g | 913 days | 20 |
| Antioxidant and Anti-Inflammatory Effects of Oral Supplementation with a Highly-Concentrated Docosahexaenoic Acid (DHA) Triglyceride in Patients with Keratoconus: A Randomized Controlled Preliminary Study 2023 · DHA group · Adults aged 18 years or older with stage I–III keratoconus | 500 mg | 90 days | 19 |
| 21 days of mammalian omega-3 fatty acid supplementation improves aspects of neuromuscular function and performance in male athletes compared to olive oil placebo 2015 · N-3 PUFA · Healthy male athletes competing in summer Olympic sports; ages not otherwise specified | 1.02 g | 3 weeks | 18 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 504 mg | 6 weeks | 16 |
| A High Omega-3 Fatty Acid Multinutrient Supplement Benefits Cognition and Mobility in Older Women: A Randomized, Double-blind, Placebo-controlled Pilot Study 2016 · Efalex Active 50+ intervention · Women aged 60 years and older, community-dwelling and able to walk at least 50 m and negotiate stairs independently; nonacutely ill | 1 g | 24 weeks | 15 |
| Effects of dietary supplementation with a combination of fish oil, bilberry extract, and lutein on subjective symptoms of asthenopia in humans 2011 · Active group · People with subjective symptoms of asthenopia; age and sex not reported | 783 mg | 4 weeks | 11 |
| Eicosapentaenoic Acid and Medium-Chain Triacylglycerol Structured Lipid Supplementation Improves Muscular Endurance Exercise Performance and Reduces Muscle Fatigue in Young Healthy Male 2025 · EPA/MCT group · Healthy young men | 260 mg | 8 weeks | 10 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 140 mg | 6 weeks | — |
| Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial 2015 · DHA/EPA and lutein/zeaxanthin · Older adults with intermediate or late age-related macular degeneration; mean age about 73 years, both sexes | 350 mg | 5 years | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 225 mg | 90 days | — |
| EPA and DHA as markers of nutraceutical treatment response in major depressive disorder 2020 · combination nutraceutical · Adults with major depressive disorder; age and sex not reported | 656 mg | 8 weeks | — |
| Effects of a Long Chain n-3 Polyunsaturated Fatty Acid-rich Multi-ingredient Nutrition Supplement on Body Composition and Physical Function in Older Adults with Low Skeletal Muscle Mass 2022 · supplement (SUPP) · Community-dwelling older adults with low skeletal muscle mass; mean age 74.9 years; 18 men and 19 women in the study overall | 1.5 g | 26 weeks | — |
| Effects of Omega-3-6-9 fatty acid supplementation on behavior and sleep in preterm toddlers with autism symptomatology: Secondary analysis of a randomized clinical trial 2022 · omega 3-6-9 treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation, with symptoms commonly associated with autism spectrum disorder | 225 mg | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 1.65 g | 16 weeks | — |
| Prenatal docosahexaenoic acid effect on maternal-infant DHA-equilibrium and fetal neurodevelopment: a randomized clinical trial 2022 · 200 mg DHA group · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks’ gestation; no specific diagnosis required | 200 mg | — | 150 |
| Docosahexaenoic Acid Supplementation for Neonatal Hyperbilirubinemia: A Double-Blind, Randomized Clinical Trial 2025 · DHA group · newborn infants with neonatal hyperbilirubinemia; sex not specified | 100 mg | — | 30 |
| Oral administration of docosahexaenoic acid attenuates interleukin-1β response and clinical course of septic neonates 2012 · G-DHA · Neonates who developed sepsis following a surgical procedure | 100 mg | 2 weeks | 29 |
| Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial 2011 · DHA 250 mg group · Children with biopsy-proven non-alcoholic fatty liver disease | 250 mg | 26 weeks | 20 |
| Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children 2013 · DHA 250 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not specified) | 250 mg | 2 years | 20 |
| Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway 2016 · DHA-treated patients · Children and adolescents aged 7–16 years with biopsy-proven NAFLD | 250 mg | 548 days | 20 |
| A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants 2019 · 200 mg/day DHA group · Mothers who delivered infants born before 28 weeks’ gestation and intended to provide breast milk; infants were extremely preterm | 200 mg | 4 weeks | 16 |
| A microalgae docosahexaenoic acid supplement does not modify the influence of sex and diet on iron status in Spanish vegetarians or omnivores: A randomized placebo-controlled crossover study 2024 · microalgae DHA supplement · Spanish usual consumers of lacto-ovo vegetarian, vegan, or omnivorous diets; age and sex not specified | 250 mg | 5 weeks | — |
| Efficacy and tolerability of calcium, vitamin D and a plant-based omega-3 oil for osteopenia: a pilot RCT 2012 · Algal oil containing DHA · Individuals with osteopenia | 400 mg | 1 year | 20 |
| Fish oil amplifies the effect of propranolol in mild essential hypertension 1990 · Third subgroup: propranolol plus fish oil · Men with mild essential hypertension | 1.1 g | 12 weeks | 16 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 1.2 g | 12 weeks | 12 |
| The effects of supplemental fish oil on blood pressure and morning cortisol in normotensive adults: a pilot study 2012 · Fish Oil (FO) · Adults, mean age 35±13 years, normotensive | 800 mg | 6 weeks | — |
| Effect of medium-term supplementation with a moderate dose of n-3 polyunsaturated fatty acids on blood pressure in mild hypertensive patients 1998 · EPA and DHA ethyl esters · Mild essential hypertensive, non-diabetic, normolipidemic male outpatients and normotensive male controls | 1.4 g | 120 days | — |
| Omega-3 fatty acid deficiency in infants before birth identified using a randomized trial of maternal DHA supplementation in pregnancy 2014 · DHA group · Pregnant women enrolled at ≤16 weeks’ gestation, without pregnancy or fetal complications and not taking lipid or fatty-acid supplements | 400 mg | — | 132 |
| Daily Enteral DHA Supplementation Alleviates Deficiency in Premature Infants 2016 · DHA · Premature infants born at 24–34 weeks’ gestational age, both sexes, at risk of DHA deficiency | 50 mg | 34 days | 31 |
| Genetic Variants in One-Carbon Metabolism and Their Effects on DHA Biomarkers in Pregnant Women: A Post-Hoc Analysis 2022 · intervention group · Healthy pregnant women aged 21–40 years, BMI <32, enrolled at 12–16 gestational weeks | 200 mg | — | 15 |
| Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC(®) 2020 · 13C-AceDoPC · Healthy men aged 60–70 years without cognitive defects | 50 mg | 1 day | 3 |
| Docosahexaenoic Acid (DHA) Bioavailability in Humans after Oral Intake of DHA-Containing Triacylglycerol or the Structured Phospholipid AceDoPC(®) 2020 · 13C-DHA-TAG · Healthy men aged 60–70 years without cognitive defects | 50 mg | 1 day | 3 |
| Supplementation with 200 mg/day docosahexaenoic acid from mid-pregnancy through lactation improves the docosahexaenoic acid status of mothers with a habitually low fish intake and of their infants 2008 · DHA-FOS group · Pregnant women enrolled at 21 weeks’ gestation with habitually low fish intake | 200 mg | — | — |
| Docosahexaenoic acid (DHA) supplementation of orange juice increases plasma phospholipid DHA content of children 2009 · lower dose · Healthy children aged 4–6 and 7–12 years | 50 mg | 6 weeks | — |
| Docosahexaenoic acid supplementation from mid-pregnancy to parturition influenced breast milk fatty acid concentrations at 1 month postpartum in Mexican women 2011 · DHA group · Pregnant women; age and condition beyond pregnancy not reported | 400 mg | — | — |
| The effect of fish oil supplementation on serum phospholipid fatty acids profile during pregnancy: A double blind randomized controlled trial 2017 · Fish oil supplementation group · Pregnant women aged 18–35 years | 120 mg | — | — |
| Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition 1996 · 0.4 g DHA/day group · Lactating mothers, randomised on day 5 postpartum | 400 mg | — | — |
| DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation 2023 · 200 mg/day DHA group · Pregnant women; ages and sex beyond being women were not specified | 200 mg | — | 524 |
| Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study 2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding | 1 g | 26 weeks | 31 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 3.7 g | 4 weeks | 21 |
| Effects of prenatal docosahexaenoic acid supplementation on offspring cardiometabolic health at 11 years differs by maternal single nucleotide polymorphism rs174602: follow-up of a randomized controlled trial in Mexico 2023 · DHA · Pregnant females; offspring were assessed at age 11 years | 400 mg | — | 160 |
| Dietary supplementation with polyunsaturated fatty acid during pregnancy modulates DNA methylation at IGF2/H19 imprinted genes and growth of infants 2014 · DHA-supplemented group · Mexican pregnant women; age and condition beyond pregnancy not reported | 400 mg | — | 131 |
| Infant Metabolome in Relation to Prenatal DHA Supplementation and Maternal Single-Nucleotide Polymorphism rs174602: Secondary Analysis of a Randomized Controlled Trial in Mexico 2021 · DHA · Pregnant women aged 18–35 years | 400 mg | — | 58 |
| DHA supplementation during pregnancy and lactation affects infants' cellular but not humoral immune response 2011 · DHA supplementation group · Pregnant women aged 20–35 years in their third or later pregnancy; infants were exclusively breast-fed through 4 months of age | 400 mg | — | 30 |
| Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial 2011 · DHA 500 mg group · Children with biopsy-proven non-alcoholic fatty liver disease | 500 mg | 26 weeks | 20 |
| Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children 2013 · DHA 500 mg/day · Children with non-alcoholic fatty liver disease (age range and sex not specified) | 500 mg | 2 years | 20 |
| Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients 2015 · DHA supplementation · Post-menopausal women with type 2 diabetes | 400 mg | 2 weeks | 11 |
| The effects of low dose n-3 fatty acids on serum lipid profiles and insulin resistance of the elderly: a randomized controlled clinical trial 2010 · intervention group · Elderly Iranian residents aged 65 or older | 120 mg | 26 weeks | — |
| Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women 2013 · EPA-rich oil capsules · Healthy men and women | 200 mg | 4 weeks | — |
| Modulation of DNA methylation states and infant immune system by dietary supplementation with ω-3 PUFA during pregnancy in an intervention study 2013 · ω-3 PUFA-supplemented group · Mexican pregnant women | 400 mg | — | — |
| Blood lipids profile in hyperlipidemic children undergoing different dietary long chain polyunsaturated supplementations: a preliminary clinical trial 2014 · DHA alone · Children aged 8–13 years with primary hyperlipidemia | 500 mg | 16 weeks | — |
| Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial 2014 · eicosapentaenoic acid-docosahexaenoic acid group · Patients aged 60–80 years with a history of myocardial infarction; 81% were men. | 159 mg | 1200 days | — |
| Docosahexaenoic acid-rich algae oil supplementation on breast milk fatty acid profile of mothers who delivered prematurely: a randomized clinical trial 2021 · S-DHA group · Mothers aged 23–28 weeks’ gestation at delivery who intended to breastfeed, with very preterm infants | 1.2 g | — | 196 |
| Effect of APOE Genotype on Plasma Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid, Arachidonic Acid, and Hippocampal Volume in the Alzheimer's Disease Cooperative Study-Sponsored DHA Clinical Trial 2020 · DHA arm · Adults with mild Alzheimer’s disease; age range and sex not specified | 2 g | 547 days | 161 |
| Supplementation with high-dose docosahexaenoic acid increases the Omega-3 Index more than high-dose eicosapentaenoic acid 2017 · DHA treatment phase · Men and women with abdominal obesity and subclinical inflammation; ages not reported | 2.7 g | 10 weeks | 154 |
| Docosahexaenoic acid (DHA) supplementation in pregnancy differentially modulates arachidonic acid and DHA status across FADS genotypes in pregnancy 2015 · DHA · Pregnant women aged 16 to 35.99 years, enrolled at 8 to 20 weeks of gestation, who were low consumers of DHA-containing foods | 600 mg | 26 weeks | 109 |
| Efficacy of docosahexaenoic acid-enriched formula to enhance maternal and fetal blood docosahexaenoic acid levels: Randomized double-blinded placebo-controlled trial of pregnant women with gestational diabetes mellitus 2016 · active-group · Pregnant women with gestational diabetes mellitus | 600 mg | — | 58 |
| The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes 2023 · 2G · NCAA Division I American-style football athletes | 2 g | 27 weeks | 18 |
| The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes 2023 · 6G · NCAA Division I American-style football athletes | 6 g | 27 weeks | 18 |
| The Dose-Response Effect of Docosahexaenoic Acid on the Omega-3 Index in American Football Athletes 2023 · 4G · NCAA Division I American-style football athletes | 4 g | 27 weeks | 15 |
| Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food 2007 · DHASCO-T capsules, 600 mg DHA/day · Adults; age, sex, and health condition not specified | 600 mg | 4 weeks | 12 |
| Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food 2007 · DHASCO-T capsules, 1,000 mg DHA/day · Adults; age, sex, and health condition not specified | 1 g | 4 weeks | 12 |
| Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food 2007 · DHASCO-S capsules, 600 mg DHA/day · Adults; age, sex, and health condition not specified | 600 mg | 4 weeks | 12 |
| Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food 2007 · DHASCO-S capsules, 1,000 mg DHA/day · Adults; age, sex, and health condition not specified | 1 g | 4 weeks | 12 |
| Randomized controlled trial of docosahexaenoic acid supplementation in midwestern U.S. human milk donors 2013 · DHA group · Lactating human milk donors; median age 31 years; no diagnosed condition reported | 1 g | — | 10 |
| Effects of docosahexaenoic supplementation and in vitro vitamin C on the oxidative and inflammatory neutrophil response to activation 2015 · supplemented group · Male professional and federated football players, mean age 19.7 years; highly trained footballers | 1.14 g | 8 weeks | 9 |
| Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study 2006 · algal oil providing DHA · patients with cystic fibrosis, aged 8 to 20 years | 50 mg/kg | 26 weeks | — |
| Docosahexaenoic acid supplementation in vegetarians effectively increases omega-3 index: a randomized trial 2005 · DHA supplementation · Healthy adult vegetarians, 87 women and 17 men | 940 mg | 8 weeks | — |
| The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation 2008 · DHA · Women aged 60–80 years | 800 mg | 120 days | — |
| Algal-oil capsules and cooked salmon: nutritionally equivalent sources of docosahexaenoic acid 2008 · Algal-oil capsules · Healthy men and women aged 20–65 years | 600 mg | 2 weeks | — |
| Toddler formula supplemented with docosahexaenoic acid (DHA) improves DHA status and respiratory health in a randomized, double-blind, controlled trial of US children less than 3 years of age 2010 · 43 mg DHA per day · Children aged 18–36 months, with no condition stated | 43 mg | 60 days | — |
| DHA supplementation and pregnancy outcomes 2013 · DHA group · Pregnant women, from before 20 weeks of gestation until birth | 600 mg | — | — |
| The effect of APOE genotype on the delivery of DHA to cerebrospinal fluid in Alzheimer's disease 2016 · DHA treatment group · Adults with probable Alzheimer’s disease, eligible with an MMSE score of 14–26; age and sex not specified | 2 g | 548 days | — |
| Combined choline and DHA supplementation: a randomized controlled trial 2020 · DHA supplementation · Preterm infants born before 32 weeks postmenstrual age | 60 mg/kg | 10 days | — |
| Compound-specific isotope analysis reveals no retroconversion of DHA to EPA but substantial conversion of EPA to DHA following supplementation: a randomized control trial 2019 · DHA group · Adults aged 21.6 ± 2.2 years; no condition stated | 3 g | 12 weeks | — |
| A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults 2020 · SEDDS AquaCelle fish oil formulation · Healthy adults | 204 mg | 1 day | — |
| A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults 2020 · Unformulated fish oil EE control · Healthy adults | 204 mg | 1 day | — |
| Different metabolism of EPA, DPA and DHA in humans: A double-blind cross-over study 2020 · DHA · Healthy women; age range not reported | 1 g | 6 days | — |
| Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition 1996 · 0.9 g DHA/day group · Lactating mothers, randomised on day 5 postpartum | 900 mg | — | — |
| Effect of maternal docosahexaenoic acid (DHA) supplementation on breast milk composition 1996 · 1.3 g DHA/day group · Lactating mothers, randomised on day 5 postpartum | 1.3 g | — | — |
| Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial 1997 · 1.25 g/day DHA · People with combined hyperlipidemia | 1.25 g | 6 weeks | — |
| Effects of docosahexaenoic acid on serum lipoproteins in patients with combined hyperlipidemia: a randomized, double-blind, placebo-controlled trial 1997 · 2.5 g/day DHA · People with combined hyperlipidemia | 2.5 g | 6 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · DHA oil group · Healthy men aged 19–32 years | 1.68 g | 14 weeks | — |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 930 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 200 mg | 12 weeks | — |
| A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the Comparing EPA to DHA (ComparED) Study 2016 · DHA · Men and women with abdominal obesity and low-grade systemic inflammation, at risk of cardiovascular disease | 2.7 g | 10 weeks | 154 |
| Prenatal docosahexaenoic acid effect on maternal-infant DHA-equilibrium and fetal neurodevelopment: a randomized clinical trial 2022 · 800 mg DHA group · Pregnant women aged 18 years or older with singleton pregnancies, enrolled at 12–20 weeks’ gestation; no specific diagnosis required | 800 mg | — | 150 |
| The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides 2006 · DHA group · Adults with coronary artery disease and triglycerides greater than 200 mg/dL | 1 g | 8 weeks | 57 |
| COMBINED INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA: Two-Year Randomized Single-Blind Controlled Trial Results 2017 · DHA supplementation group · Patients with diabetic macular edema | 1.05 g | 2 years | 29 |
| Effects of oral eicosapentaenoic acid versus docosahexaenoic acid on human peripheral blood mononuclear cell gene expression 2015 · DHA group · Men and postmenopausal women aged 21–70 with mildly elevated plasma Lp-PLA2 | 1.8 g | 6 weeks | 26 |
| Effects of lutein and docosahexaenoic Acid supplementation on macular pigment optical density in a randomized controlled trial 2013 · intervention group · Adults with early age-related macular degeneration; mean age 69.2 years, both sexes | 280 mg | 1 year | 23 |
| Docosahexaenoic acid (DHA) supplementation attenuates changes in the concentration, phenotype, and response of immune peripheral blood cells in breast cancer patients undergoing neoadjuvant therapy. Secondary findings from the DHA-WIN trial 2025 · DHA · Women with breast cancer undergoing neoadjuvant therapy; age range not specified | 4.4 g | 18 weeks | 23 |
| Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trial 2025 · DHA group · Women with newly diagnosed invasive breast cancer, stages I–III, for whom neoadjuvant chemotherapy was recommended; age range not stated | 4.4 g | 18 weeks | 23 |
| The effects of docosahexaenoic acid (DHA) on plasma cytokines, oxylipins, and tumor-infiltrating lymphocytes from women with breast cancer undergoing neoadjuvant chemotherapy in the DHA-WIN trial 2025 · DHA group · Women with breast cancer undergoing neoadjuvant chemotherapy | 4.4 g | 18 weeks | 23 |
| A comparison of the changes in cardiac output and systemic vascular resistance during exercise following high-fat meals containing DHA or EPA 2012 · DHA meal · Healthy adult males | 4.7 g | 1 day | 22 |
| EPA and DHA differentially modulate monocyte inflammatory response in subjects with chronic inflammation in part via plasma specialized pro-resolving lipid mediators: A randomized, double-blind, crossover study 2021 · DHA supplementation · Men and postmenopausal women aged 50–75 years with chronic inflammation | 3 g | 10 weeks | 21 |
| Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation 2024 · DHA supplementation phase · Adults aged 50–75 years with low-grade chronic inflammation and at least one metabolic syndrome characteristic; postmenopausal women and men | 3 g | 10 weeks | 21 |
| Co-supplementation of healthy women with fish oil and evening primrose oil increases plasma docosahexaenoic acid, gamma-linolenic acid and dihomo-gamma-linolenic acid levels without reducing arachidonic acid concentrations 2008 · FSO/EPO blend · Non-pregnant women; age range and health details beyond non-pregnant are not reported | 456 mg | 8 weeks | 20 |
| EPA + DHA supplementation reduces PMN activation in microenvironment of chronic venous leg ulcers: A randomized, double-blind, controlled study 2017 · EPA + DHA Group · Men and women aged 18–81 with chronic venous leg ulcers present for at least 3 months | 500 mg | 8 weeks | 20 |
| A Randomized Double-Blinded, Placebo-Controlled Trial Investigating the Effect of Fish Oil Supplementation on Gene Expression Related to Insulin Action, Blood Lipids, and Inflammation in Gestational Diabetes Mellitus-Fish Oil Supplementation and Gestational Diabetes 2018 · omega-3 · Women aged 18–40 with gestational diabetes mellitus and no prior history of diabetes | 240 mg | 6 weeks | 20 |
| Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy 2004 · DHA supplement, women receiving HRT · Postmenopausal women receiving hormone replacement therapy | 2.8 g | 4 weeks | 18 |
| High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2α concentrations relative to a control high-oleic acid meal: a randomized controlled trial 2014 · AO meal (high n−3 PUFA, DHA-only) · Healthy, nonsmoking men aged 35–70 years with plasma triacylglycerol concentrations >1.2 mmol/L | 10.5 g | 1 day | 16 |
| Differential eicosapentaenoic acid elevations and altered cardiovascular disease risk factor responses after supplementation with docosahexaenoic acid in postmenopausal women receiving and not receiving hormone replacement therapy 2004 · DHA supplement, women not receiving HRT · Postmenopausal women not receiving hormone replacement therapy | 2.8 g | 4 weeks | 14 |
| Effects of docosahexaenoic acid supplementation on blood lipids, estrogen metabolism, and in vivo oxidative stress in postmenopausal vegetarian women 2006 · DHA-rich algae oil group · Postmenopausal vegetarian women | 2.14 g | 6 weeks | 14 |
| The n-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid increase systemic arterial compliance in humans 2002 · DHA · Dyslipidemic subjects | 3 g | 7 weeks | 12 |
| A Randomized Trial of Maternal Docosahexaenoic Acid Supplementation to Reduce Inflammation in Extremely Preterm Infants 2019 · 1000 mg/day DHA group · Mothers who delivered infants born before 28 weeks’ gestation and intended to provide breast milk; infants were extremely preterm | 1 g | 4 weeks | 11 |
| The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients 2018 · MAG-DHA group · Adults aged 18–48 with cystic fibrosis | 3.2 g | 60 days | 10 |
| Effects of dietary Docosahexaenoic, training and acute exercise on lipid mediators 2016 · experimental beverage · Male soccer players, mean age 19.7 years, without a stated diagnosed condition | 1.14 g | 8 weeks | 9 |
| A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects 2017 · Study 103: DHA with salsalate · Healthy adults aged 18–55 years | 1.4 g | 1 day | 8 |
| The effect of docosahexaenoic acid on plasma catecholamine concentrations and glucose tolerance during long-lasting psychological stress: a double-blind placebo-controlled study 1999 · DHA group · Medical students undergoing final exams; age not reported | 1.5 g | 9 weeks | 7 |
| Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on fatty acid absorption, incorporation into serum phospholipids and postprandial triglyceridemia 1998 · DHA group · Healthy volunteers; age and sex not specified | 4 g | 5 weeks | 7 |
| Effect of docosahexaenoic acid administration on plasma lipid profile and metabolic parameters of children with methylmalonic acidaemia 2006 · DHA administration · Children with isolated methylmalonic acidaemia (MMA), mut(0); ages and sex not specified for this arm | 25 mg/kg | — | 4 |
| Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men 2000 · DHA group · Overweight, nonsmoking, mildly hyperlipidemic men; age range not reported | 4 g | 6 weeks | — |
| Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y 2001 · DHA group · Healthy adults aged 55–75 years | 720 mg | 12 weeks | — |
| Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y 2001 · Fish oil group · Healthy adults aged 55–75 years | 280 mg | 12 weeks | — |
| Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans 2001 · DHA group · Healthy adults aged 55–75 years | 720 mg | 12 weeks | — |
| Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults 2001 · DHA · Healthy adults aged 55–75 years | 700 mg | 12 weeks | — |
| Effects of purified eicosapentaenoic and docosahexaenoic acids on glycemic control, blood pressure, and serum lipids in type 2 diabetic patients with treated hypertension 2002 · DHA group · Adults with type 2 diabetes and treated hypertension; mean age 61.2 years among completers; men and postmenopausal women | 4 g | 6 weeks | — |
| Effects of purified eicosapentaenoic acid and docosahexaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients 2003 · DHA group · Treated-hypertensive men and postmenopausal women with type 2 diabetes | 4 g | 6 weeks | — |
| Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance 2003 · DHA group · Healthy subjects; age and sex not reported | 4 g | 4 weeks | — |
| Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects 1992 · Group H · Healthy men; age not reported; maintained on a high-linoleic-acid diet with saturated fatty acids kept low | 320 mg | 4 weeks | — |
| Linoleate inhibits EPA incorporation from dietary fish-oil supplements in human subjects 1992 · Group L · Healthy men; age not reported; maintained on a low-linoleic-acid, low-saturate diet | 320 mg | 4 weeks | — |
| Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects 2003 · purified DHA · Adults with treated hypertension and type 2 diabetes; mean age 61.2 years | 4 g | 6 weeks | — |
| Triacylglycerol-rich lipoprotein margination: a potential surrogate for whole-body lipoprotein lipase activity and effects of eicosapentaenoic and docosahexaenoic acids 2004 · docosahexaenoic acid (DHA) · healthy subjects; age and sex not stated | 4 g | 4 weeks | — |
| Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein 2004 · DHA-rich oil · Healthy human volunteers; age and sex not specified | 9 g | 4 weeks | — |
| Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects 2004 · DHA-rich oil · normolipidaemic adult subjects | 4.9 g | 4 weeks | — |
| Effect of docosahexaenoic acid on lipoprotein subclasses in hyperlipidemic children (the EARLY study) 2005 · docosahexaenoic acid · children with hyperlipidemia | 1.2 g | 6 weeks | — |
| Lipid responses to a dietary docosahexaenoic acid supplement in men and women with below average levels of high density lipoprotein cholesterol 2005 · DHA supplemented group · Men and women aged 21–80 years with below-average HDL cholesterol concentrations | 1.52 g | 6 weeks | — |
| Microalgal docosahexaenoic acid decreases plasma triacylglycerol in normolipidaemic vegetarians: a randomised trial 2006 · microalgae oil group · normolipidaemic adult vegetarians; 87 females and 27 males across the study | 940 mg | 8 weeks | — |
| Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins 2006 · 500 mg DHA + 400 microg 5-methyl-tetrahydrofolic acid · Healthy pregnant women during the second half of gestation | 500 mg | — | — |
| Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men 2007 · DHA oil · Men aged 39–66 years with hypertriglyceridemia | 3 g | 90 days | — |
| Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men 2008 · DHA oil · Men aged 39–66 years with hypertriglyceridemia | 3 g | 90 days | — |
| Dietary alpha-linolenic acid, EPA, and DHA have differential effects on LDL fatty acid composition but similar effects on serum lipid profiles in normolipidemic humans 2009 · DHA group · Healthy normolipidemic men and women aged 19–43 years | 2.3 g | 6 weeks | — |
| The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions 2010 · DHA · Overweight, dyslipidaemic men (Study A) and treated-hypertensive patients with type 2 diabetes (Study B) | 4 g | 6 weeks | — |
| Algal docosahexaenoic acid affects plasma lipoprotein particle size distribution in overweight and obese adults 2011 · DHA-supplemented group · Overweight or obese adults | 2 g | 135 days | — |
| Margarines fortified with α-linolenic acid, eicosapentaenoic acid, or docosahexaenoic acid alter the fatty acid composition of erythrocytes but do not affect the antioxidant status of healthy adults 2012 · DHA margarine group · Healthy men and women; age range and sex-specific numbers not reported | 2.3 g | 6 weeks | — |
| DHA-enriched high-oleic acid canola oil improves lipid profile and lowers predicted cardiovascular disease risk in the canola oil multicenter randomized controlled trial 2014 · CanolaDHA · Volunteers with abdominal obesity | 60 g | 4 weeks | — |
| Effect of DHA on plasma fatty acid availability and oxidative stress during training season and football exercise 2014 · experimental and supplemented group · Male football players; ages and health conditions not specified | 1.14 g | 8 weeks | — |
| Docosahexaenoic acid affects markers of inflammation and muscle damage after eccentric exercise 2014 · DHA · Untrained men; age and health condition not stated | 2 g | 4 weeks | — |
| Benefits of foods supplemented with vegetable oils rich in α-linolenic, stearidonic or docosahexaenoic acid in hypertriglyceridemic subjects: a double-blind, randomized, controlled trail 2015 · Docosahexaenoic acid (DHA) group · Hypertriglyceridemic subjects with triglycerides ≥ 1.5 mmol/L; age and sex not stated | 2 g | 10 weeks | — |
| Docosahexaenoic acid-enriched canola oil increases adiponectin concentrations: a randomized crossover controlled intervention trial 2015 · CanolaDHA (DHA-enriched high oleic canola oil) · Adult men and women with abdominal obesity and at least one other criterion for metabolic syndrome | 60 g | 4 weeks | — |
| Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football 2016 · 2 g·d DHA group · NCAA Division I American football athletes | 2 g | 27 weeks | — |
| Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football 2016 · 4 g·d DHA group · NCAA Division I American football athletes | 4 g | 27 weeks | — |
| Effect of Docosahexaenoic Acid on a Biomarker of Head Trauma in American Football 2016 · 6 g·d DHA group · NCAA Division I American football athletes | 6 g | 27 weeks | — |
| Docosahexaenoic diet supplementation, exercise and temperature affect cytokine production by lipopolysaccharide-stimulated mononuclear cells 2016 · experimental group · Male soccer players; age and health condition not reported | 1.16 g | 8 weeks | — |
| Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study 2016 · high-dose DHA · Children aged 6 to under 18 years with cystic fibrosis and baseline FEV1 greater than 40% predicted | 35 mg/kg | 4 weeks | — |
| Elevated prostaglandin E metabolites and abnormal plasma fatty acids at baseline in pediatric cystic fibrosis patients: a pilot study 2016 · low-dose DHA · Children aged 6 to under 18 years with cystic fibrosis and baseline FEV1 greater than 40% predicted | 25 mg/kg | 4 weeks | — |
| Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial 2016 · DHA 600mg/d · Healthy, normolipidemic subjects; age and sex not specified | 600 mg | 6 weeks | — |
| Inflammatory gene expression in whole blood cells after EPA vs. DHA supplementation: Results from the ComparED study 2017 · DHA · Men and women with abdominal obesity and low-grade inflammation, at risk for cardiometabolic diseases | 2.7 g | 10 weeks | — |
| Impact of Docosahexaenoic Acid Therapy on Subgingival Plaque Microbiota 2017 · DHA group · Adults with moderate-to-severe periodontitis | 2 g | 90 days | — |
| Comparing the serum TAG response to high-dose supplementation of either DHA or EPA among individuals with increased cardiovascular risk: the ComparED study 2019 · DHA · Men and women with increased cardiovascular risk | 2.7 g | 10 weeks | — |
| EPA and DHA have divergent effects on serum triglycerides and lipogenesis, but similar effects on lipoprotein lipase activity: a randomized controlled trial 2019 · DHA group · Young, healthy normolipidemic men and women | 3 g | 12 weeks | — |
| Time Course and Sex Effects of α-Linolenic Acid-Rich and DHA-Rich Supplements on Human Plasma Oxylipins: A Randomized Double-Blind Crossover Trial 2021 · DHA-rich supplement · Healthy men and women aged 19–34 years with BMI 18–28 kg/m² | 4 g | 4 weeks | — |
| Oils Rich in α-Linolenic Acid or Docosahexaenoic Acid Have Distinct Effects on Plasma Oxylipin and Adiponectin Concentrations and on Monocyte Bioenergetics in Women with Obesity 2021 · DHA-rich fish oil · Women aged 20–51 with obesity (BMI 30–51 kg/m²) | 4 g | 4 weeks | — |
| Increases in plasma n-3 tetracosapentaenoic acid and tetracosahexaenoic acid following 12 weeks of EPA, but not DHA, supplementation in women and men 2022 · DHA supplemented group · Women and men aged 19–30 years | 3 g | 12 weeks | — |
| Monocyte transcriptomic profile following EPA and DHA supplementation in men and women with low-grade chronic inflammation 2024 · DHA supplementation · Men and postmenopausal women aged 50–75 years with chronic low-grade inflammation and at least one cardiometabolic risk characteristic | 3 g | 10 weeks | — |
| Omega-3 fatty acids supplements for dry eye - Are they effective or ineffective? 2023 · O3FA group · Symptomatic visual display terminal users with dry eye; mean age 26.5 years; men and women | 240 mg | 180 days | 470 |
| Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid-Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis 2024 · ω-3 FA supplemented group · Healthy adults aged 20–80 years, men and women | 800 mg | 26 weeks | 92 |
| Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN) 2018 · MF4637 omega-3 concentrate · Adults aged 18 years or older with suspected non-alcoholic fatty liver disease (NAFLD) | 1.14 g | 24 weeks | 87 |
| Multiple Micronutrients and Docosahexaenoic Acid Supplementation during Pregnancy: A Randomized Controlled Study 2020 · MMS group · Healthy pregnant Caucasian women aged 18–42 years with singleton pregnancies | 200 mg | 27 weeks | 87 |
| Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN(®) REVEAL Trial 2014 · 6:1-OM3 · Adult men and women with one or more cardiovascular disease risk factors, blood Omega-Score below 6.1%, and triglycerides 1.02–5.65 mmol/L | 440 mg | 8 weeks | 56 |
| Maternal docosahexaenoic acid supplementation and fetal accretion 2003 · fish-oil capsules containing DHA · Pregnant mothers from 15 weeks gestation until term | 200 mg | — | 50 |
| Supplementation of EPA and DHA in pregnant women with type 1 diabetes mellitus 2021 · intervention group · Pregnant women aged 17–35 with type 1 diabetes mellitus and well-controlled glycaemia; supplementation began at 11–12 gestational weeks | 616 mg | — | 42 |
| Habitual diets rich in dark-green vegetables are associated with an increased response to ω-3 fatty acid supplementation in Americans of African ancestry 2014 · EPA + DHA supplementation · Participants of African ancestry; age and sex not stated | 1 g | 6 weeks | 41 |
| Effect of docosahexaenoic acid-enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition--double-blinded randomized placebo-controlled trial 2014 · fish oil, women with Type 2 diabetes · Pregnant women with Type 2 diabetes | 600 mg | — | 41 |
| Effects of a convenience drink fortified with n-3 fatty acids on the n-3 index 2010 · n-3 fatty acid drink · Adults with atherosclerotic disease and an n-3 index below 5% | 300 mg | 8 weeks | 40 |
| Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease 2017 · fish oil group · Adults with stable, mild or severe claudication due to peripheral arterial disease (Rutherford Class 1 to 3); primarily male, in their mid-sixties | 1.8 g | 30 days | 40 |
| Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults 2025 · microalgal oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL | 1.77 g | 14 weeks | 37 |
| Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans 2014 · 2 continuous portions (2C) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition | 506 mg | 1 year | 35 |
| Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial 2014 · DHA · Males aged 7–31 years with X-linked retinitis pigmentosa | 30 mg/kg | 4 years | 33 |
| Effect of Vitamin D and Docosahexaenoic Acid Co-Supplementation on Vitamin D Status, Body Composition, and Metabolic Markers in Obese Children: A Randomized, Double Blind, Controlled Study 2022 · GROUP I (vitamin D + DHA) · Children aged 6–14 years with obesity and vitamin D deficiency | 500 mg | 26 weeks | 33 |
| Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols 2016 · PL-rich herring roe oil (Romega® 30) · Adults with fasting triacylglycerol concentrations of 100–399 mg/dL; men and women | 1.81 g | 2 weeks | 32 |
| Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols 2016 · TAG-rich fish oil · Adults with fasting triacylglycerol concentrations of 100–399 mg/dL; men and women | 1.84 g | 2 weeks | 32 |
| Compared with daily, weekly n-3 PUFA intake affects the incorporation of eicosapentaenoic acid and docosahexaenoic acid into platelets and mononuclear cells in humans 2014 · 2 intermittent portions (2I) group · Adults aged 20–79 years, men and women, who reported no habitual oily-fish consumption and had no stated chronic clinical condition | 506 mg | 1 year | 30 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Soup · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 400 mg | 1 day | 27 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Extruded rice snack · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 400 mg | 1 day | 27 |
| Bioequivalence of long-chain omega-3 polyunsaturated fatty acids from foods enriched with a novel vegetable-based omega-3 delivery system compared to gel capsules: a randomized controlled cross-over acute trial 2022 · Gel capsule (control) · Apparently healthy men aged 21–50 years, Australian European or Singaporean Chinese | 400 mg | 1 day | 27 |
| Influence of Fish Consumption and ω-3 Supplementation on the ω-3 Index of Young Adults: A 2 × 2 Factorial Randomized Controlled Trial (YouFish Study) 2025 · ω-3 supplement · Healthy young adults aged 18–30 years, male and female, low habitual fish consumers with ω-3 index <6% | 300 mg | 8 weeks | 20 |
| Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults 2025 · fish oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL | 820 mg | 14 weeks | 20 |
| Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption 2016 · Calanus Oil condition · Healthy adults; age and sex not specified | 156 mg | 1 day | 18 |
| Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption 2016 · Lovaza ethyl ester condition · Healthy adults; age and sex not specified | 375 mg | 1 day | 18 |
| Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial 2022 · Control group · Pregnant participants aged 21–40 years, enrolled at 12–16 weeks’ gestation, without the specified health conditions or pregnancy complications | 200 mg | 169 days | 15 |
| Genetic Variants in One-Carbon Metabolism and Their Effects on DHA Biomarkers in Pregnant Women: A Post-Hoc Analysis 2022 · control group · Healthy pregnant women aged 21–40 years, BMI <32, enrolled at 12–16 gestational weeks | 200 mg | — | 15 |
| Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues 1994 · flaxseed group · Healthy adult men; age range not reported | 1.08 g | 8 weeks | 15 |
| Dietary substitution with an alpha-linolenic acid-rich vegetable oil increases eicosapentaenoic acid concentrations in tissues 1994 · control group · Healthy adult men; age range not reported | 1.08 g | 4 weeks | 15 |
| The effect of supplementation with docosahexaenoic and arachidonic acid derived from single cell oils on plasma and erythrocyte fatty acids of pregnant women in the second trimester 2000 · intervention group · Healthy pregnant women in the second trimester | 570 mg | 4 weeks | 12 |
| In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA 2021 · Lys-FFA · Eight female volunteers | 302 mg | 1 day | 8 |
| In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA 2021 · EE · Eight female volunteers | 378 mg | 1 day | 8 |
| Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults 1996 · 1 x · healthy adult men | 600 mg | 2 weeks | 8 |
| Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults 1996 · 3 x · healthy adult men | 1.7 g | 2 weeks | 8 |
| Plasma fatty acid responses, metabolic effects, and safety of microalgal and fungal oils rich in arachidonic and docosahexaenoic acids in healthy adults 1996 · 5 x · healthy adult men | 2.9 g | 2 weeks | 8 |
| Supplementation of arachidonic acid plus docosahexaenoic acid in cirrhotic patients awaiting liver transplantation: a preliminary study 2007 · AA/DHA group · Adults with end-stage liver disease awaiting liver transplantation | 1 g | 6 weeks | 5 |
| Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans 2004 · DHA · Healthy human subjects; age and sex not specified | 4.9 g | 4 weeks | — |
| Incorporation and clearance of omega-3 fatty acids in erythrocyte membranes and plasma phospholipids 2006 · fish oil · 20 study participants; age, sex, and health condition not specified | 864 mg | 8 weeks | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO · Pregnant women from gestation week 22 until delivery | 500 mg | — | — |
| Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial 2007 · FO with MTHF · Pregnant women from gestation week 22 until delivery | 500 mg | — | — |
| The effects of fish oil supplementation in pregnancy on breast milk fatty acid composition over the course of lactation: a randomized controlled trial 2007 · fish oil group · Pregnant women, from 20 weeks of gestation until delivery | 2.2 g | — | — |
| Erythrocyte and plasma fatty acid profiles in patients with epilepsy: does carbamazepine affect omega-3 fatty acid concentrations? 2008 · omega-3 FA supplementation · Patients with epilepsy; age and sex not reported | 700 mg | 12 weeks | — |
| The influence of supplemental lutein and docosahexaenoic acid on serum, lipoproteins, and macular pigmentation 2008 · lutein + DHA · Women aged 60–80 years | 800 mg | 120 days | — |
| Human milk arachidonic acid and docosahexaenoic acid contents increase following supplementation during pregnancy and lactation 2009 · AA+DHA · Women supplemented during pregnancy and lactation | 220 mg | — | — |
| Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters 2011 · rTAG group · Human volunteers; age, sex and health condition not specified | 670 mg | 26 weeks | — |
| Enhanced increase of omega-3 index in response to long-term n-3 fatty acid supplementation from triacylglycerides versus ethyl esters 2011 · EE group · Human volunteers; age, sex and health condition not specified | 670 mg | 26 weeks | — |
| Long-chain n-3 polyunsaturated fatty acid dietary recommendations are moderately efficient in optimizing their status in healthy middle-aged subjects with low fish consumption: a cross-over study 2014 · commercial fish oil supplement · Healthy middle-aged adults with low customary fish consumption | 250 mg | 8 weeks | — |
| Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats 2015 · Butter meal · Healthy adult men and women | 1.5 g | 1 day | — |
| Kinetics of omega-3 polyunsaturated fatty acids when co-administered with saturated or omega-6 fats 2015 · Sunflower seed oil meal · Healthy adult men and women | 1.5 g | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · unmodified fish oil TAG (uTAG) · Healthy men in the postprandial crossover study | 370 mg | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · re-esterified TAG · Healthy men in the postprandial crossover study | 370 mg | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · free fatty acids (FFA) · Healthy men in the postprandial crossover study | 370 mg | 1 day | — |
| Lipid structure does not modify incorporation of EPA and DHA into blood lipids in healthy adults: a randomised-controlled trial 2016 · ethyl esters (EE) · Healthy men in the postprandial crossover study | 370 mg | 1 day | — |
| Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions 2016 · MAG-enriched oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion | 300 mg | 3 weeks | — |
| Monoacylglycerol-enriched oil increases EPA/DHA delivery to circulatory system in humans with induced lipid malabsorption conditions 2016 · TAG fish oil · Obese adults (BMI 30–40 kg/m²), with and without Orlistat-induced lipid malabsorption/maldigestion | 300 mg | 3 weeks | — |
| Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies 2017 · Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder | 200 mg | 12 weeks | — |
| Omega-3 Fatty Acid Plasma Levels Before and After Supplementation: Correlations with Mood and Clinical Outcomes in the Omega-3 and Therapy Studies 2017 · PEP plus Ω3 supplementation · Children aged 7–14 with depression or bipolar disorder | 200 mg | 12 weeks | — |
| DHA-rich Fish Oil Increases the Omega-3 Index and Lowers the Oxygen Cost of Physiologically Stressful Cycling in Trained Individuals 2017 · DHA-rich tuna fish oil (FO) · trained males; age and health condition not specified | 560 mg | 8 weeks | — |
| Maternal Pre-Pregnancy Obesity Attenuates Response to Omega-3 Fatty Acids Supplementation During Pregnancy 2018 · n-3 PUFA supplementation group · Pregnant women with a history of at least one prior singleton preterm delivery, enrolled at 16 to 21 6/7 weeks; lean, overweight, and obese women were included | 800 mg | 8 weeks | — |
| Combined choline and DHA supplementation: a randomized controlled trial 2020 · combined choline and DHA supplementation · Preterm infants born before 32 weeks postmenstrual age | 60 mg/kg | 10 days | — |
| Plasma oxylipins and unesterified precursor fatty acids are altered by DHA supplementation in pregnancy: Can they help predict risk of preterm birth? 2020 · DHA supplementation group · Pregnant Australian women enrolled before 20 weeks of gestation; age and condition range not specified | 800 mg | — | — |
| Intake of Docosahexaenoic Acid-Enriched Milk Beverage Prevents Age-Related Cognitive Decline and Decreases Serum Bone Resorption Marker Levels 2021 · docosahexaenoic acid-enriched milk beverage · Healthy elderly Japanese individuals with a Mini-Mental State Examination score of 28 or higher at baseline | 297 mg | 1 year | — |
| Modification of serum fatty acids in preterm infants by parenteral lipids and enteral docosahexaenoic acid/arachidonic acid: A secondary analysis of the Mega Donna Mega trial 2023 · AA:DHA supplementation group · Extremely preterm infants born before 28 weeks’ gestation | 50 mg/kg | — | — |
| Effects of EPA+DHA and Corn Oil Supplementation on PUFA Concentrations across Plasma Lipid Pools and on Downstream Oxylipins: Exploratory Results from a Randomized Controlled Trial in Healthy Humans 2026 · EPA+DHA concentrate · Healthy adults aged 35–49 years; 20 women and 1 man in the available-sample analysis | 800 mg | 12 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · ethyl ester (EE) · healthy normolipaemic men | 1.2 g | 7 weeks | — |
| Comparative effects of prolonged intake of highly purified fish oils as ethyl ester or triglyceride on lipids, haemostasis and platelet function in normolipaemic men 1993 · triglyceride (TG) · healthy normolipaemic men | 1.4 g | 7 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · fish diet group · Healthy men aged 19–32 years | 670 mg | 14 weeks | — |
| Incorporation of n-3 fatty acids into plasma lipid fractions, and erythrocyte membranes and platelets during dietary supplementation with fish, fish oil, and docosahexaenoic acid-rich oil among healthy young men 1997 · fish oil group · Healthy men aged 19–32 years | 950 mg | 14 weeks | — |
| DHA, nutrient intake, and maternal characteristics as predictors of pregnancy outcomes in a randomised clinical trial of DHA supplementation 2023 · 1000 mg/day DHA group · Pregnant women; ages and sex beyond being women were not specified | 1 g | — | 576 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active group (RCT1, RCT2 and RCT3) · Men and women aged 50 years or older with mild or mild-to-moderate Alzheimer's disease; RCT3 participants were on stable approved Alzheimer's medication, while RCT1 and RCT2 participants were drug-free for Alzheimer's medication. | 1.2 g | 24 weeks | 501 |
| Prevention of Potential Adverse Metabolic Effects of a Supplementation with Omega-3 Fatty Acids Using a Genetic Score Approach 2020 · n-3 PUFA supplementation · Adults; age, sex, and health condition not specified | 1.1 g | 6 weeks | 210 |
| Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease 2015 · Active product during open-label extension (OLE) · Men and women aged 50 years or older with mild Alzheimer's disease who completed RCT2. | 1.2 g | 24 weeks | 201 |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 1.5 g | 1 year | 147 |
| Effect of Eicosapentaenoic and Docosahexaenoic Acids Added to Statin Therapy on Coronary Artery Plaque in Patients With Coronary Artery Disease: A Randomized Clinical Trial 2017 · Omega-3 ethyl-ester group · Adults aged 21–80 with stable coronary artery disease and overweight or metabolic risk features; predominantly men | 1.5 g | 913 days | 143 |
| Regression of Coronary Fatty Plaque and Risk of Cardiac Events According to Blood Pressure Status: Data From a Randomized Trial of Eicosapentaenoic Acid and Docosahexaenoic Acid in Patients With Coronary Artery Disease 2023 · EPA+DHA · Adults aged 37–80 years with stable coronary artery disease, on statin therapy | 1.5 g | 913 days | 143 |
| Effects of EPA, γ-linolenic acid or coenzyme Q10 on serum prostate-specific antigen levels: a randomised, double-blind trial 2013 · group 1 (n-3 fatty acids) · Healthy men with serum PSA ≤ 2.5 ng/ml | 2.88 g | 12 weeks | 126 |
| An omega-3 fatty acid plasma index ≥4% prevents progression of coronary artery plaque in patients with coronary artery disease on statin treatment 2019 · omega-3 ethyl esters (Lovaza) · Adults aged 21–80 with stable coronary artery disease, receiving statin treatment | 1.5 g | 913 days | 119 |
| Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n - 3 fatty acid supplementation in patients with Alzheimer's disease: the OmegAD study 2013 · n - 3/n - 3 group · Older adults with Alzheimer's disease; mean age 75 years; 57% women | 1.7 g | 1 year | 89 |
| Proteomic Profile in Retinopathy of Prematurity: A Secondary Analysis of the Mega Donna Mega Randomized Clinical Trial 2026 · AA/DHA supplementation · Extremely preterm infants born before 28 weeks’ gestational age | 50 mg/kg | — | 84 |
| Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B₄ and leukotriene B₅ production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial 2014 · n-3 FA (active) · Adults aged 41–89 with colorectal cancer awaiting surgery | 1 g | 7 days | 74 |
| Essential Fatty Acid Supplementation and Early Inflammation in Preterm Infants: Secondary Analysis of a Randomized Clinical Trial 2023 · ARA:DHA group · Extremely preterm infants born at gestational age less than 29 weeks | 50 mg/kg | — | 60 |
| Arachidonic and docosahexaenoic acid supplementation and brain maturation in preterm infants; a double blind RCT 2024 · ARA:DHA group · Infants born before 29 weeks gestational age | 50 mg/kg | — | 60 |
| Effect of Oral Re-esterified Omega-3 Nutritional Supplementation on Dry Eyes 2016 · omega-3 group · Adults over 18 years with diagnosed dry eye disease, meibomian gland dysfunction stage 1 or 2, and elevated tear osmolarity | 560 mg | 12 weeks | 54 |
| ω-3 PUFA for Secondary Prevention of White Matter Lesions and Neuronal Integrity Breakdown in Older Adults: A Randomized Clinical Trial 2024 · ω-3 group · Adults aged 75 years or older with cerebral white matter lesions and suboptimal ω-3 status; cognitively intact or with mild cognitive impairment, without dementia | 675 mg | 3 years | 51 |
| Joint effects of one year of marine omega-3 fatty acid supplementation and participant dietary fish intake upon circulating lipid mediators of inflammation resolution in a randomized controlled trial 2024 · n-3 fatty acid supplementation · Women aged 55 years or older and men aged 50 years or older; participants selected from the VITAL trial by baseline fish intake, without a stated diagnosis | 380 mg | 1 year | 50 |
| Effects of Fatty Acid Therapy in Addition to Strong Statin on Coronary Plaques in Acute Coronary Syndrome: An Optical Coherence Tomography Study 2020 · EPA+DHA group · Adults with acute coronary syndrome after successful PCI; age and sex mix not restricted | 750 mg | 1 year | 48 |
| Effect of eicosapentaenoic acid and docosahexaenoic acid supplementation on C-peptide preservation in pregnant women with type-1 diabetes: randomized placebo controlled clinical trial 2017 · Study group · Pregnant women with type-1 diabetes mellitus | 1.23 g | — | 47 |
| Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids 2013 · n-3 PUFA / fish oil treatment · Adults with type 2 diabetes and hypertension, and adults with hypertension without diabetes; age- and sex-matched groups | 380 mg | 8 weeks | 45 |
| A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha 2002 · 300 mg DHA + 70 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported | 300 mg | 4 weeks | 40 |
| A randomized trial of supplementation with docosahexaenoic acid-rich tuna oil and its effects on the human milk cytokines interleukin 1 beta, interleukin 6, and tumor necrosis factor alpha 2002 · 600 mg DHA + 140 mg EPA · Lactating mothers of healthy full-term infants; age and sex beyond lactating women are not reported | 600 mg | 4 weeks | 40 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 1.8 g | 30 days | 40 |
| DHA-enriched fish oil reduces insulin resistance in overweight and obese adults 2020 · FO (fish oil) intervention · Men and women with abdominal obesity, without diabetes; mean age 50.9 ± 12.7 years | 860 mg | 12 weeks | 38 |
| Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines 2018 · EPA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history | 274 mg | 14 weeks | 37 |
| Dietary Omega-3 Fatty Acid Supplementation Reduces Inflammation in Obese Pregnant Women: A Randomized Double-Blind Controlled Clinical Trial 2015 · ω-3 FA supplement arm · Overweight or obese pregnant women (BMI ≥25), generally healthy, enrolled at 8–16 weeks’ gestation | 800 mg | 25 weeks | 36 |
| Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes 2017 · n-3 PUFAs · Adults, mean age 65.6 years, men and women, with type 2 diabetes and established atherosclerotic cardiovascular disease | 1 g | 90 days | 36 |
| Effect of prenatal EPA and DHA on maternal and umbilical cord blood cytokines 2018 · DHA-rich fish oil · Pregnant women at 12–20 weeks’ gestation with risk of depression, based on Edinburgh Postnatal Scale score 9–19 or past depression history | 900 mg | 14 weeks | 36 |
| Dietary supplementation with docosahexaenoic acid rich fish oil increases circulating levels of testosterone in overweight and obese men 2020 · DHA-enriched fish oil (FO) · Overweight and obese men and women without diabetes; testosterone analysis focused on men | 860 mg | 12 weeks | 32 |
| DHA-rich n-3 fatty acid supplementation decreases DNA methylation in blood leukocytes: the OmegAD study 2017 · n-3 FA group · Patients with Alzheimer disease; age and sex not reported | 1.7 g | 26 weeks | 30 |
| Atherothrombogenic risk modulation by n-3 fatty acids was not associated with changes in homocysteine in subjects with combined hyperlipidaemia 1999 · n-3 fatty acids · Adults with combined (type IIb) hyperlipidaemia who had not responded to a therapeutic diet | 4 g | 12 weeks | 28 |
| Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers 2014 · Lovaza 1/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years | 375 mg | 7 weeks | 28 |
| Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial 2017 · ω-3 supplement group · Children and adolescents aged 7–14 years with mood disorders, including bipolar disorder, major depressive disorder, or dysthymic disorder | 200 mg | 12 weeks | 28 |
| Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations 2020 · Nutrient supplement phase, healthy participants · Healthy adults aged 20–65 years | 510 mg | 4 weeks | 27 |
| Marine ω-3 PUFA Supplementation Enhances FFAR4 Activation and Reduces Inflammatory Markers in PBMC of Subjects with Obesity: A Randomized Controlled Trial (EPICO) 2025 · marine-derived ω-3 · Adults aged 25–59 years with obesity or abdominal obesity, without major health complications | 720 mg | 8 weeks | 26 |
| Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study 2002 · group 2 (Maxigard group) · Adults with type 2 diabetes and BMI <27 kg/m²; age and sex not specified | 240 mg | 6 weeks | 25 |
| Lipid mediator serum profiles in asthmatics significantly shift following dietary supplementation with omega-3 fatty acids 2013 · ω-3 FA · Adults aged 20–54 with clinically diagnosed mild-to-moderate asthma | 2 g | 3 weeks | 25 |
| Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b 2013 · fish oil group · Adults aged 18–55 with relapsing-remitting multiple sclerosis, treated with interferon beta-1b | 1.6 g | 1 year | 25 |
| Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers 2014 · Lovaza 4/day · Healthy men and non-pregnant, non-lactating women aged 18–45 years | 1.5 g | 7 weeks | 25 |
| Effects of oral supplementation with omega-3 fatty acids on nutritional state and inflammatory markers in maintenance hemodialysis patients 2014 · omega-3 group · Adults undergoing maintenance hemodialysis | 720 mg | 120 days | 25 |
| Generation and dietary modulation of anti-inflammatory electrophilic omega-3 fatty acid derivatives 2014 · fish oil group (treatment) · Healthy adults aged 30–54 years, employed at least 25 hours per week, with dietary EPA and DHA consumption below 300 mg/day | 400 mg | 120 days | 24 |
| Urinary metabolite profiles in premature infants show early postnatal metabolic adaptation and maturation 2014 · intervention group · Premature infants with birth weight below 1500 g | 60 mg/kg | 4 weeks | 24 |
| Omega-3 Fatty Acid Could Increase One of Myokines in Male Patients with Coronary Artery Disease: A Randomized, Double-Blind, Placebo-Controlled Trial 2017 · Omega-3 · Men with coronary artery disease and more than 50% stenosis in at least one major coronary vessel | 480 mg | 8 weeks | 24 |
| Cytokine distribution in mothers and breastfed children after omega-3 LCPUFAs supplementation during the last trimester of pregnancy and the lactation period: A randomized, controlled trial 2017 · FO group · Pregnant women recruited at week 28 of pregnancy and followed through lactation | 320 mg | — | 24 |
| Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism 2020 · omega-3 FA group · Men aged 35–55 years with fasting plasma TAG concentrations of at least 1.5 mmol/L; nondiabetic and free from known disease | 1.52 g | 8 weeks | 24 |
| Effects of an Omega-3 and Vitamin D Supplement on Fatty Acids and Vitamin D Serum Levels in Double-Blinded, Randomized, Controlled Trials in Healthy and Crohn's Disease Populations 2020 · Nutrient supplement phase, participants with Crohn's disease · Adults aged 20–65 years with Crohn’s disease in remission | 510 mg | 6 weeks | 24 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 1.45 g | 6 weeks | 21 |
| Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults 2021 · EPA+DHA Group · Adults aged 50–85 with chronic inflammatory conditions, including nonhealing venous leg ulcers; overweight or obese older adults | 1 g | 8 weeks | 21 |
| Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial 2016 · Treatment arm · Children and adolescents aged 4–16 years with biopsy-proven NAFLD and serum vitamin D deficiency | 500 mg | 24 weeks | 20 |
| N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial 2022 · n-3 FA · Caucasian men and women aged 50–79 with combined hyperlipidemia, taking stable atorvastatin | 1 g | 8 weeks | 20 |
| Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study 2023 · high-dose EPA/DHA group · Adults aged 20 years or older receiving hemodialysis and diagnosed with dyslipidemia | 1.5 g | 90 days | 19 |
| The effect of highly purified eicosapentaenoic and docosahexaenoic acids on monocyte phagocytosis in man 1997 · highly purified DHA · healthy men | 3.6 g | 7 weeks | 19 |
| Dietary supplementation with fish oil in ulcerative colitis 1992 · fish oil · Adults with active ulcerative colitis | 2.16 g | 120 days | 18 |
| Brain delivery of supplemental docosahexaenoic acid (DHA): A randomized placebo-controlled clinical trial 2020 · DHA treatment arm · Cognitively unimpaired men and women aged 55 years and older with a first-degree family history of dementia | 2.15 g | 26 weeks | 18 |
| DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men 2009 · DHA oil group · Men aged 39–66 with hypertriglyceridemia | 3 g | 90 days | 17 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 900 mg | 7 weeks | 17 |
| Effects of Dietary n-3 Fatty Acids on Hepatic and Peripheral Insulin Sensitivity in Insulin-Resistant Humans 2015 · n-3 (EPA+DHA) · Overweight insulin-resistant, nondiabetic adults; 8 men and 23 women were randomized, ages not stated | 600 mg | 26 weeks | 16 |
| Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: A randomized, controlled study 2018 · EPA+DHA Group · Men and women aged 50–85 with chronic venous leg ulcers diagnosed for at least 3 months | 1 g | 8 weeks | 16 |
| Omega-3 Fatty Acids Reduce Remnant-like Lipoprotein Cholesterol and Improve the Ankle-Brachial Index of Hemodialysis Patients with Dyslipidemia: A Pilot Study 2023 · low-dose EPA/DHA group · Adults receiving hemodialysis and diagnosed with dyslipidemia who continued after the initial control period | 750 mg | 90 days | 16 |
| Supplementation of postmenopausal women with fish oil rich in eicosapentaenoic acid and docosahexaenoic acid is not associated with greater in vivo lipid peroxidation compared with oils rich in oleate and linoleate as assessed by plasma malondialdehyde and F(2)-isoprostanes 2000 · Fish oil · Postmenopausal women | 1.4 g | — | 15 |
| Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate 2001 · fish oil (FO) · Postmenopausal women; ages and health conditions not specified | 1.4 g | — | 15 |
| Omega-3 fatty acids effect on wound healing 2008 · EPA/DHA supplement group · Healthy men and women aged 18–45 years | 1.1 g | 5 weeks | 15 |
| [Metabolic syndrome reversion by polyunsaturated fatty acids ingestion] 2013 · n-3 group · Adults with metabolic syndrome | 720 mg | 6 weeks | 15 |
| Dietary supplementation with low-dose omega-3 fatty acids reduces salivary tumor necrosis factor-α levels in patients with chronic periodontitis: a randomized controlled clinical study 2017 · test group · Systemically healthy patients with chronic periodontitis; age and sex not reported | 19.2 mg | 26 weeks | 15 |
| Supplementation of Re-Esterified Docosahexaenoic and Eicosapentaenoic Acids Reduce Inflammatory and Muscle Damage Markers after Exercise in Endurance Athletes: A Randomized, Controlled Crossover Trial 2020 · DHA + EPA · Healthy male amateur endurance athletes aged 18–45 years | 2.1 g | 10 weeks | 15 |
| Prenatal choline supplementation improves biomarkers of maternal docosahexaenoic acid (DHA) status among pregnant participants consuming supplemental DHA: a randomized controlled trial 2022 · Intervention group · Pregnant participants aged 21–40 years, enrolled at 12–16 weeks’ gestation, without the specified health conditions or pregnancy complications | 200 mg | 171 days | 15 |
| An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia 2004 · Omacor · 14 patients with familial combined hyperlipidemia (FCHL); age range and sex not reported | 1.48 g | 8 weeks | 14 |
| Effects of alpha-linolenic acid versus those of EPA/DHA on cardiovascular risk markers in healthy elderly subjects 2006 · EPA/DHA-rich diet · Healthy mildly hypercholesterolemic adults aged 60–78 years, 14 men and 23 women across the study | 550 mg | 6 weeks | 14 |
| Effect of eicosapentaenoic and docosahexaenoic acid on resting and exercise-induced inflammatory and oxidative stress biomarkers: a randomized, placebo controlled, cross-over study 2009 · EPA/DHA · Exercise-trained men; ages 25.5 ± 4.8 years; no stated cardiovascular or metabolic disorders | 2.21 g | 6 weeks | 14 |
| Effects of dietary n-3 polyunsaturated fatty acids from plant and marine origin on platelet aggregation in healthy elderly subjects 1999 · EPA/DHA diet, elderly subjects · Adults older than 60 years, healthy elderly subjects | 550 mg | 6 weeks | 13 |
| Fatty acid absorption in preterms on formulas with and without long-chain polyunsaturated fatty acids and in terms on formulas without these added 2001 · Group PB · Preterm newborns receiving preterm formula supplemented with arachidonic acid and docosahexaenoic acid | 10 mg/kg | 3 days | 13 |
| Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial 2020 · n-3 PUFA group · Adults aged 19 years or older, both sexes, with ultrasound-confirmed non-alcoholic fatty liver disease | 1.51 mg | 26 weeks | 13 |
| Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study 2014 · EPA group · Adults older than 65 years with mild cognitive impairment | 160 mg | 26 weeks | 12 |
| Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled pilot study 2014 · DHA group · Adults older than 65 years with mild cognitive impairment | 1.55 g | 26 weeks | 12 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · High DHA-FO concentrate · Obese men and women with BMI >30 | 2 g | 12 weeks | 12 |
| Effects of DHA-rich n-3 fatty acid supplementation on gene expression in blood mononuclear leukocytes: the OmegAD study 2012 · n-3 FA group · Patients aged 54–82 with mild to moderate Alzheimer’s disease | 1.7 g | 26 weeks | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 1.8 g | 90 days | 11 |
| Supplementation with dietary ω-3 mitigates immobilization-induced reductions in skeletal muscle mitochondrial respiration in young women 2019 · ω-3 supplementation · Healthy young women, age 22 ± 3 years | 2 g | 6 weeks | 11 |
| The influence of low intake of n-3 fatty acids on platelets in elderly people 1999 · n-3 PUFA group · healthy elderly people; age range and sex not stated | 150 mg | 6 weeks | 10 |
| Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer 1992 · fish oil group · Patients with sporadic adenomatous colorectal polyps; age and sex not reported | 3.6 g | 12 weeks | 10 |
| Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial 2012 · FO-N (normolipidemic fish oil group) · Men aged 29–51 years with normolipidemia | 1.14 g | 12 weeks | 10 |
| Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition 2000 · fish oil extract · Patients with procto-colitis; age and sex not reported | 2.4 g | 26 weeks | 9 |
| Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds 2011 · Active Group (EPA + DHA supplement) · Healthy adults aged 18–45 years, both sexes | 1.2 g | 4 weeks | 9 |
| Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial 2012 · FO-D (dyslipidemic fish oil group) · Men aged 29–51 years with dyslipidemia | 1.14 g | 12 weeks | 9 |
| [Effect of short-term use of omega-3-type polyunsaturated fatty acids in subjects with hypertriglyceridemia] 1992 · fish oil · Patients with hypertriglyceridemia; age and sex not reported | 1.2 g | 12 weeks | 8 |
| Metabolic effects of fish-oil supplementation in patients with impaired glucose tolerance 1991 · fish-oil supplementation · Obese adults with impaired glucose tolerance; mean age 50.3 years; sex not reported | 2.5 g | 2 weeks | 8 |
| Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects 1994 · fish oil · Subjects without cystic fibrosis; mean age 13.4 years | 2.2 g | 6 weeks | 8 |
| Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects 1994 · fish oil · Patients with cystic fibrosis and pancreatic insufficiency; mean age 12.2 years | 2.2 g | 6 weeks | 7 |
| Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia 2020 · n-3 supplementation · Six subjects with hypertriglyceridemia; age and sex not reported | 240 mg | 60 days | 6 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · EPA and DHA (3.4 g/day) · Healthy men aged 29–32 years | 1.52 g | 8 weeks | 3 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · 1800 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group | 700 mg | 150 days | 2 |
| Identification of specialized pro-resolving mediator clusters from healthy adults after intravenous low-dose endotoxin and omega-3 supplementation: a methodological validation 2018 · 900 mg/d EPA and DHA · Healthy adults; Study A participants aged 21–28 years, 2 men and 1 woman in the supplement group | 350 mg | 150 days | 1 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 1 g | 12 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 1.1 g | 12 weeks | — |
| Effect of a fish-oil concentrate on serum lipids in postmenopausal women receiving and not receiving hormone replacement therapy in a placebo-controlled, double-blind trial 2000 · n-3 fatty acid-enriched oil supplement · Postmenopausal women, receiving or not receiving hormone replacement therapy | 1.6 g | 4 weeks | — |
| Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo-Asians 2004 · Fish-oil group · British Indo-Asian Sikhs and Europeans; adults, age and weight matched between ethnic groups | 1 g | 12 weeks | — |
| Influence of an algal triacylglycerol containing docosahexaenoic acid (22 : 6n-3) and docosapentaenoic acid (22 : 5n-6) on cardiovascular risk factors in healthy men and women 2006 · Active treatment · Healthy men and women | 1.5 g | 4 weeks | — |
| Docosahexaenoic acid supply in pregnancy affects placental expression of fatty acid transport proteins 2006 · 500 mg DHA + 150 mg eicosapentaenoic acid · Healthy pregnant women during the second half of gestation | 500 mg | — | — |
| Arachidonic acid and docosahexaenoic acid supplementation increases coronary flow velocity reserve in Japanese elderly individuals 2008 · PUFA · Japanese elderly individuals, mean age 65 years; no condition stated | 240 mg | 90 days | — |
| Influence of a concentrated ethylester compound of n-3 fatty acids on lipids, platelets and coagulation in patients undergoing coronary bypass surgery 1991 · n-3 fatty acids · Patients eligible for coronary bypass surgery with fasting triglyceride levels of at least 1.6 mmol/L | 1.89 g | 26 weeks | — |
| Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women 2008 · fish oil (FO) · pregnant women; age and health condition not specified | 500 mg | — | — |
| Effects of docosahexaenoic acid-rich n-3 fatty acid supplementation on cytokine release from blood mononuclear leukocytes: the OmegAD study 2008 · n-3 FAs group · Alzheimer disease patients | 1.7 g | 26 weeks | — |
| Fish oil supplementation lowers C-reactive protein levels independent of triglyceride reduction in patients with end-stage renal disease 2009 · fish oil group · Patients with end-stage renal disease; age range and sex not reported | 600 mg | 26 weeks | — |
| Effect of n-3 oral supplements on the n-6/n-3 ratio in young adults 2010 · experimental group · healthy young adults | 1.2 g | 4 weeks | — |
| Th1 and Th2 chemokines, vaccine-induced immunity, and allergic disease in infants after maternal ω-3 fatty acid supplementation during pregnancy and lactation 2011 · ω-3 fatty acid supplementation · Pregnant women at risk of having an allergic infant | 1.1 g | — | — |
| ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation 2011 · fish oil · African American adults aged 20–59 years, 68% female; no specific condition stated | 1 g | — | — |
| [Effect on the lipid profile of diet supplemented with fish oil concentrate] 1990 · n-3 treated group · male and female patients with cholesterol values higher than 7.0 mmol/l | 1.5 g | 12 weeks | — |
| Fish oil supplementation in early infancy modulates developing infant immune responses 2012 · fish oil group · Infants of high atopic risk, from birth; sex not specified | 280 mg | 26 weeks | — |
| Efficacy of omega-3 fatty acid supplementation on serum levels of tumour necrosis factor-alpha, C-reactive protein and interleukin-2 in type 2 diabetes mellitus patients 2012 · treatment group · Adults aged 45–85 years with type 2 diabetes mellitus for at least two years | 828 mg | 8 weeks | — |
| Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load 2012 · n-3 PUFAs · Patients with combined dyslipidemia; age and sex not specified | 1.35 g | 26 weeks | — |
| Eicosapentaenoic and docosahexaenoic acid supplementations reduce platelet aggregation and hemostatic markers differentially in men and women 2013 · DHA-rich oil capsules · Healthy men and women | 1 g | 4 weeks | — |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 100 mg | 1 year | — |
| Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder 2012 · n-3 group · Children aged 6–12 years with ADHD receiving maintenance therapy | 195 mg | 8 weeks | — |
| Effect of docosahexaenoic acid supplementation on inflammatory cytokine levels in infants at high genetic risk for type 1 diabetes 2015 · DHA treatment group (Groups A and B) · Infants with a first-degree relative with type 1 diabetes and HLA DR3 and/or DR4, or multiple first-degree relatives with type 1 diabetes; Group A treatment began in the last trimester of pregnancy and Group B treatment began in the first five postnatal months | 1.2 g | 3 years | — |
| Omega-3 fatty acids' effect on leptin and adiponectin concentrations in patients with spinal cord injury: A double-blinded randomized clinical trial 2015 · treatment group · Patients with spinal cord injury; age and sex not stated | 930 mg | 426 days | — |
| Effect of omega-3 fatty acids on kidney function after myocardial infarction: the Alpha Omega Trial 2014 · eicosapentaenoic acid-docosahexaenoic acid plus α-linolenic acid group · Patients aged 60–80 years with a history of myocardial infarction; 81% were men. | 159 mg | 1200 days | — |
| Effects of n-3 FA supplementation on the release of proresolving lipid mediators by blood mononuclear cells: the OmegAD study 2015 · n-3 FA treatment · Patients with Alzheimer's disease | 1.7 g | 26 weeks | — |
| Effects of Iron Supplementation With and Without Docosahexaenoic Acid on the Cardiovascular Disease Risk Based on Paraoxonase-1, hs-CRP, and ApoB/ApoA-I Ratio in Women with Iron Deficiency Anemia 2016 · DHA supplement with iron tablet · Women aged 15–45 years with iron deficiency anemia | 500 mg | 12 weeks | — |
| The Pattern of Fatty Acids Displaced by EPA and DHA Following 12 Months Supplementation Varies between Blood Cell and Plasma Fractions 2015 · 1 portion per week · Healthy non-oily-fish-consuming adults; age range and sex distribution not stated | 253 mg | 1 year | — |
| The effect of 12-wk ω-3 fatty acid supplementation on in vivo thalamus glutathione concentration in patients "at risk" for major depression 2015 · ω-3 FA supplements · Older adults at risk for depression; age range and sex not specified | 800 mg | 12 weeks | — |
| A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease 2017 · krill oil · People with mild to moderate dry eye disease; age and sex not reported | 510 mg | 90 days | — |
| A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease 2017 · fish oil · People with mild to moderate dry eye disease; age and sex not reported | 500 mg | 90 days | — |
| Effect of diets rich in either saturated fat or n-6 polyunsaturated fatty acids and supplemented with long-chain n-3 polyunsaturated fatty acids on plasma lipoprotein profiles 2017 · SFA-rich diet · Healthy subjects; age and sex not reported | 2 g | 6 weeks | — |
| Effect of diets rich in either saturated fat or n-6 polyunsaturated fatty acids and supplemented with long-chain n-3 polyunsaturated fatty acids on plasma lipoprotein profiles 2017 · n-6PUFA-rich diet · Healthy subjects; age and sex not reported | 2 g | 6 weeks | — |
| Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: A double blind, randomized controlled clinical trial 2017 · omega-3 fatty acid group · Infants from birth to 6 months of age | 280 mg | 26 weeks | — |
| Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults 2020 · EPA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease | 1.5 g | 8 weeks | — |
| Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults 2020 · DHA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease | 3.6 g | 8 weeks | — |
| Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity 2020 · fish oil · Adults aged 50–80 years with overweight or obesity (BMI 25–40 kg/m²) | 2 g | 16 weeks | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + placebo · Overweight or obese pregnant women at increased risk for gestational diabetes | 1.9 g | — | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + probiotics · Overweight or obese pregnant women at increased risk for gestational diabetes | 1.9 g | — | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 800 mg | 12 weeks | — |
| Eicosapentaenoic and docosahexaenoic acid supplementation and coronary artery calcium progression in patients with coronary artery disease: A secondary analysis of a randomized trial 2023 · EPA + DHA · Adults aged 37–80 years with stable coronary artery disease | 1.5 g | 900 days | — |
| The Effect of Eicosapentaenoic and Docosahexaenoic Acid Supplementation on Coronary Artery Calcium Progression in Subjects With Diabetes and Coronary Artery Disease: A Secondary Analysis of a Randomized Trial 2024 · EPA+DHA supplementation · Adults with coronary artery disease on statin therapy, with and without diabetes | 1.5 g | 913 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 DHA plus EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 350 mg | 5 years | — |
| Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis 1995 · fish oil treatment group · Patients with mild rheumatoid arthritis; age and sex not reported | 1.1 g | 26 weeks | — |
| Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels 1996 · fish oil group · Healthy male university students | 950 mg | 15 weeks | — |
| Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels 1996 · DHA-oil group · Healthy male university students | 5.68 g | 15 weeks | — |
| Use of a Micronutrient Cocktail to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Adults with Obesity: A Randomized, Double-Blinded Pilot Clinical Trial 2024 · intervention group · Adults aged 18–70 with obesity and dyslipidemia | 280 mg | 90 days | 105 |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 90 mg | 10 weeks | 24 |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · SynΩ3 group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 83.4 mg | 4 weeks | 24 |
| The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial 2017 · Test product (Souvenaid/Fortasyn Connect) · Adults aged 50 years or older with mild probable or possible Alzheimer’s disease | 1.2 g | 4 weeks | 16 |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 1.2 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 200 mg | — | 10 |
| A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone 2021 · risperidone + FO · Patients aged 15–40 with recent-onset psychosis, including schizophrenia-spectrum disorders or bipolar disorder | 400 mg | 16 weeks | 10 |
| Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye 2011 · omega-3 group · Patients with dry eye; age and sex not reported | 300 mg | 90 days | — |
| Reproductive state and choline intake influence enrichment of plasma lysophosphatidylcholine-DHA: a post hoc analysis of a controlled feeding trial 2019 · 480 mg choline per day group · Healthy non-pregnant, third-trimester pregnant, and lactating women; reproductive groups were included in the analysis | 200 mg | 12 weeks | — |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 120 mg | 4 weeks | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 350 mg | 5 years | — |
| The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial 2024 · Group (2) / EP (EPA plus placebo) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women | 400 mg | 12 weeks | 25 |
| The effect of curcumin and high-content eicosapentaenoic acid supplementations in type 2 diabetes mellitus patients: a double-blinded randomized clinical trial 2024 · Group (3) / CE (curcumin plus EPA) · Adults aged 18 years or older with type 2 diabetes and HbA1c >5.8%; mean age 56.40 years; men and women | 400 mg | 12 weeks | 25 |
| Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity 2020 · combination · Adults aged 50–80 years with overweight or obesity (BMI 25–40 kg/m²) | 2 g | 16 weeks | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 3 years | 399 |
| Effect of docosahexaenoic acid-enriched fish oil supplementation in pregnant women with Type 2 diabetes on membrane fatty acids and fetal body composition--double-blinded randomized placebo-controlled trial 2014 · fish oil, healthy women · Healthy pregnant women | 600 mg | — | 45 |
| Decreased cord blood IL-4, IL-13, and CCR4 and increased TGF-beta levels after fish oil supplementation of pregnant women 2008 · fish oil (FO) and methyl-tetra-hydrofolic acid · pregnant women; age and health condition not specified | 500 mg | — | — |
| Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects 2021 · DHA · healthy volunteers | 4 g | 30 days | — |